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Chapter 1
General Introduction
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Well into the 21st century, the human brain remains a mystery. Although human brain de-
velopment follows the same principles as that of all mammals1,2, there are clear interspecies 
differences that ultimately lead towards the unique cognitive and behavioral features of hu-
mans3,4. Primarily the cerebral cortex is responsible for the higher cognitive, abstract thinking 
and language capacities humans contain3,4.
Humans have an exceptionally long gestational time, childhood and adolescence2,5–7. Ana-
tomically the human brain has an extended surface area and the amount of vertical columns in 
the cortex has increased in number, size and complexity1,8. This has resulted in a large change 
in cell number9,10, morphology and composition of brain cells11,12.
Genetic differences between humans and our closely related ancestors9,13–16 and the latest 
humans to become extinct, Neanderthals and Denisovans17,18, are reflected in single-nucleotide 
variants, insertions, deletions and structural chromosomal rearrangements18. The majority 
of alterations are found in developmental genes and their regulatory regions18–20. Especially 
the latter may have significantly contributed to human brain evolution, as regulatory genes 
function selectively in cell types and during specific cell cycles, adding extra layers of control 
of expression13,18,21,22.
Nonetheless, human brain evolution and extended life span also appears to have given rise 
to susceptibility for brain diseases, such as neurodegenerative diseases23 and psychiatric dis-
orders24–26. In humans amongst others the processes of dendritic and synaptic maturation and 
synaptic pruning are prolonged27. This prolonged period links it to various neuropsychiatric 
disorders and intellectual disabilities28–30. Also many genes associated with neuropsychiatric 
disorders are involved in brain development and its regulation, which contains several human-
specific processes31,32. Similarly, white matter volume in the prefrontal cortex is disproportion-
ally larger in human brains33,34, but progressively declines in the aging brain, linking human 
oligodendrocyte function to several neurodegenerative diseases35.
To shed light on the molecular mechanisms of human brain diseases, studies are commonly 
performed in animal models, the mouse being highly suitable for its genetic resemblance and 
ease to work with2. Yet, the human brain is over 1000 times larger than the mouse brain3, its 
cortical genesis takes roughly 20 times longer3, its cell cycle time is 3-4 times longer3, birth 
occurs during later stages of brain development and postnatal maturation takes longer before 
reproduction. Also, in development there is compartmentalization of the different neural 
progenitors and layers, such as a larger transient subplate zone and an outer subventricular 
zone as well as expanded superficial layers of the cortex. Also human glia are unique and 
distinctively different from rodent glia36–38. They are considerably larger in size, have more 
elaborate processes and physiology and form more connections.
One way to study particularly human brain development and the cells of the human brain 
is by using human embryonic stem (hES) cell technology. Human embryonic stem cell 
technology emerged in the late 1990s. It comprises the use of pluripotent stem cells from pre-
implanted embryos. These cells in theory have the capacity to differentiate into the different 
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cell types that can be found in the human brain. A couple of commonly used hES cell lines 
are the H1, H9 and H11 lines39 and protocols to tweak these cells towards the neural lineages 
appeared soon after their establishment in 1998. Most of these protocols are based on existing 
procedures to derive neural precursor cells (NPCs) from mouse stem cells40. Fundamental 
studies on human stem cell-derived neural cells though stayed surprisingly limited. A reason 
for this may have been the ethical and limited disease-modeling capacity of hES cells.
In 2006 Yamanaka et al. published their work on in vitro reprogramming of somatic cells 
towards induced pluripotent stem (iPS) cells41. With the overexpression of the four embryonic 
transcription factors Oct3/4, Sox2, Klf4, and c-Myc in terminally differentiated cell types, 
somatic cells are driven back to an induced pluripotent state. In many ways, iPS cells are 
morphologically and transcriptionally similar to hES cells42. They have the capacity to dif-
ferentiate to different germ layers and terminally differentiate towards specific cell types. This 
has offered a less ethically controversial way to generate human brain cell types and allowed 
diseasemodeling in which the differentiated neural cells retain the genome of the donor.
DeveloPMenT of THe HuMan CereBral CorTex
The question that emerged however is to what extent iPS technology could be applied to study 
human brain development and model human brain diseases.
Cortical development involves neurogenesis, differentiation, migration, synaptogenesis, 
and establishment and refinement of connections4. In humans it spans early to mid-gestational 
periods, although myelination takes up to the 2nd and 3rd decade of life. Human neurodevel-
opment starts with the formation of the neural tube from the embryonic ectoderm7,43. The 
wall of the neural tube contains a pseudostratified layer of neuroepithelial cells called the 
ventricular zone (VZ). These cells are the progenitors for all neurons and glial cells (astrocytes 
and oligodendrocytes) in the brain and spinal cord. Rounds of symmetric division of the 
neuroepithelial cells which give rise to two identical progenitor daughter cells, each round 
of replication increasing the pool of neural progenitor cells. Rounds of asymmetric division 
produce one progenitor cell and one post-mitotic neuron per division. To form the corti-
cal plate, cells radially migrate from the VZ44. The cortex is shaped in an inside-out fashion. 
Neurons residing in deeper layers emerge first and newly generated neurons migrate through 
these layers to form the more superficial layers44.
Every cell in the different layers of the cortex has a distinct transcriptional profile related 
to its cellular composition and relative maturity. Neurons find their place in the cortex using 
somal translocation. The neuron extends one process, which is an extension of the cell body 
beyond the VZ into the outer region. The process then attaches to the pial surface, the outer 
surface of the brain. Subsequently, the nucleus then moves up the process and migrates out of 
the VZ. When the brain becomes larger, radial glial (RG) cells serve as guides for migrating 
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neurons. Their nucleus remains in the VZ and they extend their processes to the pial surface. 
Migrating neurons use their process as a scaffold to migrate into the brain. RGs themselves 
also serve as a neural progenitor pool. Next, a second proliferative zone emerges above the VZ, 
called the subventricular zone (SVZ). These cells give rise to the majority of the glutamatergic 
neurons within the telencephalon.
During development, several layers are discernable (figure 1)7,43. The first neurons that 
leave the VZ form the preplate (PP). The next wave of migrating neurons splits the PP in the 
marginal zone (MZ) and the subplate (SP). The neurons that establish between these layers 
are the first cells of the cortical plate (CP). Both the MZ and the CP are transient layers, and 
disappear with development. The MZ moreover contains Cajal-Retzius cells, a heterogeneous 
population of cells that produce reelin, a secreted extracellular matrix protein responsible for 
migration and positioning of neurons into layers of the neocortex45. Subsequently, the SVZ 
emerges and from the VZ up to the MZ the following layers are present: VZ, SVZ, intermedi-
ate zone (IZ), SP, CP, MZ. The VZ and SVZ will eventually reduce to a one-cell-layer thick 
region and the IZ will develop into a white matter layer above which the 6 layers of the cortex 
have developed.
figure 1, schematic model of human neocortical development (adapted from Bystron et al. 200843). CP, corti-
cal plate; IZ, intermediate zone; SP, subplate zone; MZ, marginal zone; SVZ, subventricular zone; (SG), subpial 
granular layer (part of the MZ); VZ, ventricular zone.
Another proliferative zone in the developing brain is the ganglionic eminence (GE). Here 
important classes of inhibitory neurons and oligodendrocytes precursor cells (OPCs) are 
generated. These cells migrate tangentially into the cortex44.
Most of the knowledge regarding early brain development is derived from rodents where 
tracing studies with labeled virus can indicate cell progeny. Limited evidence exists on early 
human VZ/SVZ development. A few studies however confirm and highlight similarities and 
dissimilarities between rodents and human VZ development. Most knowledge is obtained by 
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immunostaining of primary cell cultures and slice cultures from human fetal brains. More 
recently, with the development of single-cell RNA sequencing technology progenitors and 
neurons are re- and sub-classified on the basis of their RNA expression next to their im-
munogenic profile46.
THe venTrICular zone
Several groups have described different cell types in the VZ during human brain develop-
ment. The first cell types to be identified were RG and neuron-restricted progenitors47–50. At 
4,5 gestational weeks (gw) RG are exclusively present in the VZ47. Immunophenotypically, RG 
are characterized by the expression of glia-specific antigens, such as the intermediate filament 
vimentin51 or nestin, astrocyte-specific glutamate transporter (GLAST)52 and glial fibrillary 
acidic protein (GFAP)47,49. Actively dividing RGs are visualized using the 4A4 antibody, which 
recognizes vimentin phosphorylated by a mitosis-specific kinase, cdc2 kinase53. When RG 
divide, their cell bodies descend to the ventricular surface to undergo mitosis (interkinetic 
nuclear migration)1. RG serve as a guide for migrating neurons, but eventually develop into 
neurons, astrocytes or oligodendrocyte precursor cells (OPCs). Occasionally therefore RGs 
in this stage are also found to express SMI-31, a marker of nonphosphorylated intermediate 
filament proteins, present in cells of neuronal lineage47.
At similar ages neuron-restricted progenitors are also found47–50. These are dividing cells that 
stain positive for neuronal markers such as SMI-31, β-III-tubulin, MAP2 and doublecortin 
(DCX) and negative for any of the RG markers. They are also present in the pro-encephalon,
where no RGs are present47.
At 5-6 gw neurogenesis starts in humans48. At 5,5 gw mitotically active RG are found about 
100 um above the VZ surface47. At 6 gw active RGs are found throughout the entire pro-
encephalon. Next to this, neurogenic progenitors are found throughout the VZ and SVZ. They 
are dividing vertically or horizontally with respect to the VZ surface. There is also an actively 
dividing GLAST+ and β-III-tubulin+ population at the ventricular surface, perhaps indicating 
RG that will develop into neurons.
By 9-10 gw the cortical plate, a layer of 6 cells thick, is visible in the entire telencephalic 
wall47. RG are abundant and dividing. Many also have migrated to the SVZ and IZ. RG are 
reaching up into the SVZ, the IZ and CP47. These RG do not express neuronal and glial mark-
ers simultaneously49. 
That RG become restricted in their fate was also indicated by Mo et al50. They isolated RG 
from 14 and 20 gw VZ/SVZ using immunopanning with CD15, an extracellular matrix-asso-
ciated carbohydrate50. Over 90% of the CD15+ population co-labeled for one of the following 
RG markers: BLBP, vimentin or GFAP. Only less than 10% of the CD15+ co-stained for β-III-
tubulin. When clonal cultures of individual CD15+ cells were analyzed, four types of clones 
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were discernable: pure GFAP+ clones, pure MAP2+ clones, mixed clones with a majority of 
GFAP+ cells, and mixed clones with a majority of MAP2+ clones. More glia were generated in 
cultures derived from the 20 gw-old VZ/SVZ than from the 14 gw-old VZ/SVZ, indicating 
that stage differences may play a part in their fate determination. 
That the RG population itself is heterogeneous was also confirmed by Howard et al. who 
studied dissociated cell cultures obtained from VZ/SVZ of 19-22 gw fetuses47. Of the total 
population of dividing cells in culture roughly 30% was vimentin+ or GFAP+ and about 15% 
was GLAST+. Many glial cells would simultaneously express several markers. It was unclear 
though if the expression of different antigens determines RGs ability to develop into either 
neurons, astrocytes or OPCs or that it is a function of cell differentiation.
Which factors play a part in fate-determination remains largely unknown. One however 
entails regional cues50. Mo et al. co-cultured CD15+ cells with GE and cortical cells. They 
showed that CD15+ cells co-cultured with the GE developed into calretinin+ interneurons 
considerably more often than when CD15+ cells were co-cultured with cortical cells50. They 
also found that growth factors EGF and FGF were higher in cultures containing neurogenic 
RGs, pointing towards which cues specifically play a role in fate-determination.
At 17-24 gw RG are still dividing but less so than at 9-10 gw47. In midgestation RGs are in 
all compartments of the telencephalon, such as the IZ and the most superficial subpial granule 
layer. In the VZ some calretinin+ 4A4- cells are visible. They are closely apposed to the RG 
fibers as if using them as a guide.
By midgestation 20 gw, most of neurogenesis has taken place. RG start to transform into 
GFAP+ astrocytes in the intermediate zone and the cortical plate48. Occasionally there is mito-
sis of the RG, but by 23 gw proliferation has finished49. An ependymal layer forms on the VZ. 
Thin GFAP+ fibers cross it to attach to the VZ surface49.
THe SuBvenTrICular zone
From 5-6 gw the VZ is the only proliferative zone. At 7-8 gw the SVZ emerges above the 
VZ54,55. Cells that are generated from the ventricular epithelium populate it. Here prolifera-
tion continues until the 40 gw-long intra-uterine period. From 10-24 gw the appearance of 
the SVZ changes because of tangentially incoming fibers from subcortical regions and those 
crossing the corpus callosum54. There are cell fibers visible that stretch to the subplate. The 
fibers divide the SVZ in the inner (iSVZ) and outer SVZ (oSVZ).
Several classes of progenitors are found in the SVZ56. One resembles RG in phospho-
vimentin, nestin and GFAP expression and is also Pax6+ and Sox2+ 56. In contrast to RG 
though these cells have basal processes extending to the pia, but lack an apical process that is 
connected to the surface of the VZ. They are termed outer radial glia cells (oRG). In contrast 
to RG that show interkinetic nuclear migration, these cells show mitotic somal translocation 
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where the nucleus moves up the basal fiber before cell division. As the cell divides the upper 
cell inherits the basal process, whereas the lower cell becomes bipolar, generating an oRG and 
an oSVZ progenitor. This is an example of asymmetric self-renewing division. Both oRG and 
oSVZ progenitors are able to divide again. The oRG is able to yet again asymmetrically divide, 
whereas the oSVZ generates two similar daughter cells. This process ensures rapid expansion 
of the progenitor pool. Hansen et al. also found that daughter oSVZ cells can readapt oRG 
morphology56.
Outer RG develop into excitatory neurons54–56. From 7-27 gw β-III-tubulin+, PSA-NCAM+ 
and MAP2+ immature neurons are present in the SVZ56. TBR-1+ and glutamate+ cells are pres-
ent, labeling projection neurons, which were migrating radially to the upper cortical layers54. 
NeuN+ and NSE+ cells are mostly visible away from the SVZ in the subplate, the cortical plate 
and layer I54.
However, from 7-22 gw Zecevic et al. also found GABA+, calretinin+, and calbindin+ inhibi-
tory neurons54. They had unipolar or bipolar morphology, suggestive of their migration. In 
slice cultures of 22 gw-old VZ/SVZ a BrdU-incorporation proliferation assay showed that 
25% of the BrdU+ cells expressed Dlx and19% expressed Nkx2.1, indicating these cells were 
progenitors to interneurons. Yet, 55% of the Dlx+ cells and 80% of the Nkx2.1+ were also 
PDGRFα+, an early oligodendrocyte progenitor marker, signifying that in the SVZ progeni-
tors to both interneurons and OPCs are present.
Hansen et al. similarly found progenitors of interneurons. By following division of oRG in 
real-time and determining daughter cell fate by immunostaining, they showed that daughter 
cells can start to express TBR-2, an indicator of commitment to the neuronal lineage and 
newly-born neurons of the excitatory lineage, or ASCL1, a transcription factor to indicate 
GABAergic fate.
At 25-27 gw the VZ becomes a one-cell-layer thick ependymal layer whereas the SVZ is 
still present around the lateral ventricle54. The subependymal zone contains neural stem cells, 
which then remain throughout adulthood for repair processes57.
InTerneuronS
In contrast to rodents, in humans two-thirds of the interneurons are generated in the SVZ58–64.
The first-born GABAergic interneurons are generated in the GE in the basal ganglia and 
migrate tangentially into the CP. The first wave of migration contains pioneer neurons that 
make up the early PP. These contain different types of cells, including Cajal-Retzius cells. 
Production of interneurons in the GE is followed by generation of interneurons in the SVZ. 
In the mature brain several classes of interneurons are found. They are roughly divided by 
their expression of the neurochemical markers parvalbumin (PV), somatostatin (STT) and 
serotonin receptor 3A (Htr3a) and are further subdivided based on morphological features, 
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cellular and subcellular targeting, electrophysiological and synaptic properties as well as ex-
pression of other markers65–67. This classification is largely based on studies in mice and serves 
as a starting point for understanding the interneuron diversity in humans.
Several studies shed light on the development of interneurons in the human brain. The 
GE is the main source of interneurons in early brain development (6-15 gw)42,50–52. In mice a 
regulatory network of the transcription factors Dlx1, Dlx2, Ascl1, Gsx1 and Gsx2 is required 
for the generation of interneurons in the subpallium70,71. In humans Dlx+ and Nkx2.1+ pro-
genitors for interneurons are also found and migrate tangentially to the developing neocortex. 
They develop into calretinin+ and calbindin+ interneurons in the deeper layers V and VI of 
the neocortex58. At 15 gw the GE is still the main source of cortical interneurons, as indicated 
by calretinin labeling58. From 16-24 gw however, Dlx+ 63, Nkx2.1+ 63, Ascl1+ 60 and Gsx2+ 64 
populations are also discernable in the VZ/SVZ. These cells regularly co-localize with markers 
GABA, GAD2 or calbindin. VZ/SVZ RG that are Pax6+ and BLBP+ are also able to produce 
interneurons64. Yu et al. also confirmed the presence of RG that are GABA+ and calretinin+ 63.
At midgestatin Ascl1+ cells are also found in the GE. There they co-label with Dlx59,62. In 
the VZ however, Ascl1+ and Dlx+ cells do not co-localize, nor do Ascl1+ and Nkx2.1+ cells, 
indicating distinct populations of precursor interneurons. Also, there was very little overlap 
between Ascl1+ and calretinin+ progenitors. Ascl1+ cells however were GABA+, so they may 
give rise to another interneuron subtype. Ascl1+ cells were however sometimes also labeled 
with PDGRFα, but most of these cells were seen in the cortical plate, especially in the sub-
plate59. Its percentage was much lower in the VZ/SVZ. Therefore in midgestation Ascl1+ 
interneurons and Ascl1+ OPC progenitors are present. There are also Ascl1+ cells that express 
neither of these markers and therefore they are either not committed to cell fate yet or part of 
the interneuron and OPC lineage but at time of examining not expressing GABA or PDGRFα.
Neuropeptide Y+, somatostatin+ and parvalbumin+ interneurons are sparse in midgesta-
tion58 and are generated later in human neurodevelopment.
GlIal CellS: olIGoDenDroCyTeS anD aSTroCyTeS
Oligodendrocyte lineage cells have the highest turnover in the central nervous system and all 
ages of the cell are present throughout the brain at all times. OPC development starts in 2nd 
trimester and continues after birth72,73. PDGFRα+ cells are visualized at 10 gw in the forebrain 
for the first time, but the highest number of these cells is around 15 gw, when they are present 
mostly in the GE and VZ/SVZ. Cells with similar morphology as PDGFRα+ cells were often 
also labeled with NG2-chondroitin sulfate proteoglycans72. By midgestation 19-22 gw OPCs 
invade more dorsal areas as well as the cortical plate. During the majority of development 
OPCs are most dense in the SVZ. At around 20-22 gw O4+ and O1+ OPCs are present in the 
subplate layer, immediately below the cortical plate. As they mature they start to express MBP 
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and PLP. The first MBP+ cells with mature morphology are seen at 18 gw. There is a ventral 
to dorsal progression of oligodendrogenesis. During development several classes of OPCs 
are discernable: there is a population that expresses Dlx2, Nkx2.1, present in both GE and 
VZ, a Dlx2- and Nkx2.1- class, and a class of OPCs expressing PDGRFα, NG2, Olig1, nestin, 
and also CD34 and CD6872,73. Next to this humans contain a subpopulation of NPCs that are 
Olig2+ and Pax6+ in cryosections of 15-20gw in GE and SVZ, indicating human-specific OPC 
populations.
Human astrocyte development is mostly unknown. In rodents astrocytes develop from 
transformation of RG, glial progenitors in the SVZ, glial progenitors in the MZ/layer I or from 
progenitors in the superficial layers of the cortex74. DeAzevedo et al. describes the transition of 
RG into astrocytes in human brain from 18 to 39 gw75. Transition is described by detachment 
of the ventricular process, followed by detachment of the pial process. However, also pial 
detachment before ventricular detachment is seen. In the late stages of astrocytes develop-
ment stellate morphology is discerned. From 38-39 gw astrocytes are bilaminarly distributed. 
GFAP+ and vimentin+ astrocytes are seen in the upper CP and MZ and in the SP/IZ. After 
detachment of either of the processes, nuclei of the astrocytes migrate radially to their place 
in the cortex.
Most astrocytes nonetheless are generated after birth36. In adult humans four classes of 
astrocytes are found: protoplasmic astrocytes, interlaminar astrocytes, polarized astrocytes 
and varicose projection astrocytes37,38. It is unclear though how and when these develop.
MoDelInG HuMan neural CellS wITH IPS CellS
Regardless of the complexity of the human brain, the generation of neural cell types that 
resemble bona fide neural cells at the level of RNA, antigen expression and/or functionality 
have been generated using iPS as cell source.
Most protocols to classically differentiate neural cells from iPS are based on or modified 
from protocols to generate neural cells from mouse ES or hES cells. The majority of the proto-
cols rely on mimicking the extracellular environment in utero76. In short, two pathways exist: 
guiding towards neuroepithelium with growth-factors and morphogens versus dual-SMAD 
inhibition76. In such a way neural progenitor cells (NPCs) are produced. They are then cultured 
for terminal differentiation into neurons or glial cells77,78. Protocols are also available to enrich 
for specified neurons such as cholinergic79, dopaminergic79, GABAergic80 and serotonergic81,82 
populations. By combination of growth factors and mere time, cell populations could also be 
enriched for astrocytes83,84, OPCs85 and oligodendrocytes86.
It became clear that the development in vitro was mimicking the order of development in 
vivo87. Many neuron-generating protocols show a neural rosette stage resembling neural tube 
formation76,88. This stage recapitulates progenitor zones similar to the VZ and SVZ including 
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its mixed population of progenitors. In vitro emergence of astrocytes and myelination takes 
place after terminal neuronal division also mimicking in vivo neurodevelopment. As a conse-
quence, more so than a model for adult human brain neurons, stem cell-derived neurons in 
vitro represent best first trimester (up to 12gw) human fetal neurons89,90, which are generated 
in at least 6 weeks in vitro from a neural progenitor stage91. Also, certain protocols recapitulate 
some structures of second trimester brain development92. As such, next to modeling specific 
cell types, human iPS technology allows modeling early human brain development93.
Enhanced maturation is seen by using 3D culturing techniques92,94,95. Combinations of 
growing iPS in gels and scaffolds96, or the self-organizing capacity of iPS in suspension are 
used to generate adherent 3D neural cultures, or free-floating brain organoids respectively97. 
The 3D environment allows next-level development of structures with enhanced and more 
mature capabilities84 and model gene expression programs of fetal brain development98. 3D 
models have come as far as modeling hippocampal and cortical layers99,100 as well as forebrain, 
midbrain and hypothalamic structures 92,101, where further development of the culture is com-
monly held back by lack of in vitro vascularization capacity99. However, recently Mansour 
et al.102 implanted brain organoids in the mouse brain and showed enhanced development 
and vascularization, paving the way towards developmental progression of iPS-derived neural 
models and enhanced understanding of the brain and brain-related disease using iPS-based 
models.
SCoPe of THIS THeSIS
In this thesis we explore the use of IPS for modeling human brain development and disease.
In chapter 2 we describe a neural differentiation protocol that produces electrophysiologi-
cal functional neural networks. This protocol allows for examination of iPS-derived neural 
networks for disease-related studies.
In chapter 3 we study the transcriptional regulation of human BDNF. Using our protocol 
described in chapter 2 we find novel BDNF transcripts in humans that are expressed upon 
activity of neural cells.
In chapter 4 we study the subcellular localization of mouse and human UBE3A in neurons, 
the lack of which in neurons causes the neurodevelopmental disorder Angelman Syndrome. 
We find differential localization of mouse and human UBE3A protein isoforms.
In chapter 5 we study the epigenetic modifications of the FMRI1 gene. The absence of the 
FMRI1 gene product, fragile X mental retardation protein (FMRP), causes the intellectual 
disability disorder Fragile X syndrome. We find that standard reprogramming procedures 
lead to epigenetic silencing of the fully mutated FMR1 gene also in rare healthy individuals 
who carry a full mutation of FMRI1 but show no hypermethylation of the gene’s CGG repeats 
and promoter.
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In chapter 6 we study long non-coding RNA (lncRNA) variants associated with Alzheimer’s 
disease (AD). We find an associated variant that mediates regulation of AD-related genes in 
iPS-derived neural cells.
In chapter 7 I discuss the limitations of iPS technology that influence its capacity to model 
human brain diseases. I also discuss potential solutions.
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aBSTraCT
Progress in elucidating the molecular and cellular pathophysiology of neuropsychiatric disor-
ders has been hindered by the limited availability of living human brain tissue. The emergence 
of induced pluripotent stem cells (iPSCs) has offered a unique alternative strategy using 
patient-derived functional neuronal networks. However, methods for reliably generating 
iPSC-derived neurons with mature electrophysiological characteristics have been difficult to 
develop. Here, we report a simplified differentiation protocol that yields electrophysiologi-
cally mature iPSC-derived cortical lineage neuronal networks without the need for astrocyte 
co-culture or specialized media. This protocol generates a consistent 60:40 ratio of neurons 
and astrocytes that arise from a common forebrain neural progenitor. Whole-cell patch-clamp 
recordings of 114 neurons derived from three independent iPSC lines confirmed their electro-
physiological maturity, including resting membrane potential (-58.2 ± 1.0 mV), capacitance 
(49.1 ± 2.9 pF), action potential (AP) threshold (-50.9 ± 0.5 mV), and AP amplitude (66.5 
± 1.3 mV). Nearly 100% of neurons were capable of firing APs, of which 79% had sustained 
trains of mature APs with minimal accommodation (peak AP frequency: 11.9 ± 0.5 Hz) and 
74% exhibited spontaneous synaptic activity (amplitude, 16.03 ± 0.82 pA; frequency, 1.09 ± 
0.17 Hz). We expect this protocol to be of broad applicability for implementing iPSC-based 
neural network models of neuropsychiatric disorders.
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InTroDuCTIon
A detailed knowledge of the pathophysiology underlying the majority of human neuropsychi-
atric disorders remains largely enigmatic. However, functional genomic studies have begun 
to offer novel insights into many forms of neurological and psychiatric illness1–5. There is 
widespread consensus that validated and robust human cellular models for brain disorders 
would be of considerable benefit6,7.
The discovery of induced pluripotent stem cells (iPSCs) has provided the opportunity to 
investigate the physiology of living human neurons derived from individual patients8. Several 
protocols have been reported for generating iPSC-derived neurons based on a variety of dif-
ferent methods. One of the most commonly employed approaches is neural induction through 
embryoid body (EB) formation9,10. Another widely implemented method for neural induction 
is inhibition of the transforming growth-factor-b-SMAD signaling pathway by Noggin and 
SB431542, which provides highly efficient neural conversion of iPSCs into midbrain dopa-
mine and spinal motor neurons11,12. More recently, protocols have been developed for generat-
ing three-dimensional (3D) neural cultures using cerebral organoids cultured in a spinning 
bioreactor13, cortical spheroids in free-floating conditions14, or in 3D Matrigel culture15.
In establishing optimized and standardized methods for neuronal differentiation of iPSCs, 
one of the most important questions is the functional maturity of the resulting neuronal 
networks. The design of optimized neural differentiation protocols is critical for the reliable 
generation of functional neurons that can form active networks and demonstrate mature elec-
trophysiological properties. Bardy et al. recently reported a significant advance in achieving 
functionally mature iPSC-derived neural networks16. However, the major limitation with this 
approach is the requirement for a non-standard culture medium and extracellular recording 
solution during the differentiation process and electrophysiological recordings.
Neuron-astrocyte interactions are critical both during early neurodevelopment and in the 
adult brain17. Astrocytes are involved in the guidance of neuronal precursors and for increas-
ing the length of neuronal fiber projections during development18. In addition, astrocytes 
dynamically modulate synaptic transmission19,20. Consequently, the functional maturation of 
human pluripotent stem cell-derived neurons is substantially improved by the presence of 
astrocytes14,21. For the derivation of iPSC-derived neural networks, astrocytes can either be in-
troduced through co-culture22 or differentiated from a common neural progenitor which gives 
rise to both neurons and astrocytes as occurs in vivo10. The co-culture approach allows more 
flexibility in having experimental control over the neuron-to-astrocyte ratio and the source 
of the co-cultured astrocytes. The major drawback, however, is the potential for introducing 
a source of variability, especially concerning species differences when using co-cultures of 
rodent astrocytes with human iPSC-derived neurons. In contrast, differentiation protocols 
based on a common progenitor giving rise to both neurons and astrocytes proceed more 
similarly to in vivo neurodevelopment9,10.
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Using the latter approach, we now report a simplified differentiation protocol for deriving 
functionally mature neural networks from iPSCs without the need for astrocyte co-culture or 
specialized media.
MaTerIal anD MeTHoDS
Human iPSC lines
Reprogramming of human primary skin fibroblasts from two adult donors (Line 1: male, age 
57; line 2: female, age 54) was performed as described previously using a single, multicistronic 
lentiviral vector encoding OCT4, SOX2, KLF4, and MYC23. Both donors provided written 
informed consent, in accordance with the Medical Ethical Committee of the Erasmus Univer-
sity Medical Center. Quality control of iPSC clones was performed by karyotyping, real-time 
quantitative PCR, and embryoid body differentiation24. Line 3 (male, newborn) was repro-
grammed from cord blood CD34+ cells using episomal reprogramming (Axol Biosciences).
Differentiation of human iPSCs to neural networks
Generation of Neural Precursor Cells (NPCs)
Human iPSC lines 1 and 2 were dissociated from MEFs with collagenase (100 U/ml, Thermo 
Fisher Scientific) for 7 minutes at 37°C/5% CO2. Embryoid bodies (EBs) were generated by 
transferring dissociated iPSCs to non-adherent plates in human embryonic stem cell medium 
[DMEM/F12 (Thermo Fisher Scientific), 20% knockout serum (Thermo Fisher Scientific), 
1% MEM-NEAA (Sigma-Aldrich), 7 nl/ml β-mercaptoethanol (Sigma), 1% L-glutamine 
(Thermo Fisher Scientific), 1% penicillin/streptomycin (P/S, Thermo Fisher Scientific)] on a 
shaker in an incubator at 37°C/5% CO2. EBs were grown for two days in human embryonic 
stem cell medium, changed into neural induction medium [DMEM/F12, 1% N2 supplement 
(Thermo Fisher Scientific), 2 μg/ml heparin (Sigma-Aldrich), 1% P/S] on day 2, and cultured 
for another four days in suspension (d3-d6). For generation of NPCs, EBs were slightly dis-
sociated at d7 by trituration and plated onto laminin-coated 10 cm dishes [20 μg/ml laminin 
(Sigma-Aldrich) in DMEM for 30 min at 37°C], initially using neural induction medium 
(d7-14), and then from d15 in NPC medium [DMEM/F12, 1% N2 supplement, 2% B27-RA 
supplement (Thermo Fisher Scientific), 1 µg/ml laminin, 20 ng/ml FGF2 (Merck-Millipore), 
and 1% P/S]. On d15, cells were considered pre-NPCs (passage 1) and able to be passaged 
(1:4) and cryopreserved when confluent. From passage 5, cells were considered NPCs and 
used for neural differentiation.
Line 3 NPCs were derived using the protocol reported by Shi et al.10 with modifications 
(Axol Biosciences, line ax0015) to examine the generalizability of our neural differentiation 
protocol.
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Neural Differentiation
For neural differentiation, NPCs (passage 5-11) were plated on sterile coverslips in 6-or 
12-well plates, coated with polyornithine (Sigma-Aldrich) for 1 hour at room temperature. 
Coated coverslips were washed 3 times with sterile water and dried for 30 min. Subsequently, a 
100 µl drop of laminin solution (50 µg/ml in water) was placed in the middle of each coverslip, 
incubated for 15-30 min at 37°C/5% CO2, and then replaced with a 100 µl drop of DMEM 
until plating of NPCs. Immediately prior to plating, NPCs were washed with Dulbecco’s 
phosphate buffered saline (DPBS) and dissociated with collagenase (100 U/ml). One fully 
confluent 10 cm dish of NPCs was divided over a 12-well plate. A 100 µl drop of NPC cell 
suspension was placed on the laminin-coated spot for 1 hour to allow for attachment of NPCs 
on coverslips in neural differentiation medium [Neurobasal medium, 1% N2 supplement, 
2% B27-RA supplement, 1% MEM-NEAA, 20 ng/ml BDNF (ProSpec Bio), 20 ng/ml GDNF 
(ProSpec Bio), 1 µM db-cAMP (Sigma-Aldrich), 200 µM ascorbic acid (Sigma-Aldrich), 2 μg/
ml laminin, and 1% P/S]. After 1 hour, 900 µl of neural differentiation medium was added to 
each well. Cells were refreshed with medium 3 times per week. During weeks 1-4, medium 
was fully refreshed. After 4 weeks of neural differentiation, only half of the volume of medium 
per well was refreshed. Electrophysiology and confocal imaging were performed between 
8-10 weeks after plating of NPCs.
Immunocytochemistry and quantification
Cell cultures were fixed using 4% formaldehyde in PBS. Primary antibodies were incubated 
overnight at 4°C in labelling buffer containing 0.05 M Tris, 0.9% NaCl, 0.25% gelatin, and 0.5% 
Triton-X-100 (pH 7.4). The following primary antibodies were used: SOX2, Nestin, MAP2, 
TBR1, GAD67, NeuN and glial fibrillary acidic protein (GFAP) (Merck-Millipore); FOXG1 
(ProSci); Vimentin (Santa Cruz Biotechnology); AFP (R&D Systems); TRA-1-81 and Nanog 
(Beckton Dickinson); OCT4, BRN2, SATB2, CUX1, CUX2 and CTIP2 (Abcam); Synapsin, 
MAP2 (Synaptic Systems); and PSD95 (Thermo Fisher Scientific). The following secondary 
antibodies were used: Alexa-488, Alexa-546, Alexa-555 and Cy3 antibodies (Jackson Immu-
noResearch). Samples were imbedded in Mowiol 4-88 (Sigma-Aldrich) after which confocal 
imaging was performed with a Zeiss LSM700 confocal microscope using ZEN software (Zeiss, 
Germany).
electrophysiology
Whole-cell patch clamp recordings
Culture slides were collected from 12-well culture plates. Whole-cell patch clamp recordings 
were performed at 8-10 weeks following the initiation of NPC differentiation. Recording 
micropipettes (tip resistance 3–6 MΩ) were filled with internal solution composed of (mM): 
130 K-gluconate, 0.1 EGTA, 1 MgCl2, 2 MgATP, 0.3 NaGTP, 10 HEPES, 5 NaCl, 11 KCl, 5 
Na2-phosphocreatine (pH 7.4). Recordings were made at room temperature using a Multi-
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Clamp 700B amplifier (Molecular Devices). Signals were sampled and filtered at 10 kHz and 
3 kHz, respectively. The whole-cell capacitance was compensated and series resistance was 
monitored throughout the experiment in order to confirm the integrity of the patch seal and 
the stability of the recording. Voltage was corrected for liquid junction potential (-14 mV). 
The bath was continuously perfused with oxygenated artificial cerebrospinal fluid (ACSF) 
composed of (mM): 110  NaCl, 2.5  KCl, 2  CaCl2, 10  glucose and 1 NaH2PO4, 25 NaHCO3, 0.2 
ascorbic acid, 2 MgCl2 (pH 7.4). For voltage-clamp recordings, cells were clamped at −80 mV. 
Spontaneous postsynaptic currents (sPSCs) were recorded for 3 minutes. Fast sodium and 
potassium currents were evoked by voltage steps ranging from −80 to +50 mV in 10 mV 
increments. Capacitance was derived from the Clampex 10.2 membrane-test function. For 
current-clamp recordings, voltage responses were evoked from a holding potential of -75 mV 
using 500 msec steps ranging from −20 to +150 pA in 10 pA intervals delivered at 0.5 Hz. 
Single action potential properties were calculated from the first evoked AP in response to a 
depolarizing step.
Spontaneous AP activity was measured for 3 minutes using the minimum hyperpolarizing 
holding current in which spiking was evident (0–10 pA), from an initial holding potential 
of -80 mV. Action potential threshold was calculated as the second derivative of the AP 
waveform. AP rise and decay times were calculated at 10% and 90% of the AP amplitude, 
respectively. Data analysis was performed by Clampfit 10.2 (Molecular devices). Spontaneous 
postsynaptic currents were analyzed by MiniAnalysis software (Synaptosoft).
Equilibration procedure from cell culture medium to ACSF
Before initiating whole-cell recordings, cell culture medium was gradually replaced with oxy-
genated ACSF in order to minimize the impact of the relative difference in osmolarity (culture 
medium, 220 mOsm/L; ACSF, 305 mOsm/L). Into the 1 mL volume of culture medium per 
well, 300 µl of oxygenated ACSF was added for 5 minutes, after which 300 µl was removed. 
This replacement procedure was repeated 5 times at room temperature. Slides were placed 
immediately thereafter into the recording chamber with continuous perfusion of oxygenated 
ACSF.
Biocytin labeling
Juxtasomal labeling of neurons was performed using biocytin (5% w/v internal solution) at 
8 weeks following the initiation of NPC differentiation. With a GΩ seal on the cell soma, 
neurons were subjected to 15–20 min of 100–150 pA square-wave current pulses delivered 
at 2 Hz. Cultures were fixed using 4% formaldehyde in phosphate-buffered saline. Secondary 
staining with Alexa-488- streptavidin (Jackson ImmunoResearch) was performed in labeling 
buffer overnight at 4 °C, after which slides were mounted in Mowiol 4-88 and imaged with 
a Zeiss LSM700 confocal microscope using ZEN software (Zeiss). Sholl analysis and den-
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drite length quantification were performed using Fiji (ImageJ, National Institutes of Health, 
Bethesda, MD, USA) software25.
electron Microscopy
Fixation was performed for 1 h in 2% glutaraldehyde and 0.1 M sodium cacodylate (NaCac). 
After rinsing in 0.1 M NaCac, cells were pelleted in 2% agar and postfixed in 2% glutaral-
dehyde for 15 min. Subsequently, cells were osmicated for 1 h with 1% OsO4, dehydrated 
with EtOH and propylene oxide, followed by embedding in Durcupan Plastic (Fluka) for 72 
h. Ultrathin sections (60 nm) were cut using an ultramicrotome (Leica), mounted on nickel 
grids and counterstained with uranyl acetate and lead citrate. Imaging was performed with a 
CM100 Transmission Electron Microscope (Philips).
Statistical analysis
Statistical comparisons of continuous variables were performed using analysis of variance 
(ANOVA) with post-hoc Tukey’s test, using SPSS (Version 21, IBM). For categorical param-
eters, Fisher’s Exact Test was used. The threshold for statistical significance was set at P<0.01 
in order to correct for the 17 different electrophysiological parameters measured.
reSulTS
Generation of forebrain-patterned nPCs from iPSCs
Neural Precursor Cells (NPCs) are capable of generating a diversity of neural lineages, includ-
ing both neurons and astrocytes. To generate iPSC-derived NPCs (lines 1 and 2), iPSCs were 
detached from feeder cells using collagenase and suspended colonies were transferred to non-
adherent plates (Supplementary figure 1). Suspended colonies were cultured on a shaker, 
which promoted the formation of spherical embryoid bodies (EBs) (figure 1a). EBs were 
cultured for six days (d1-d6), of which the first two days (d1-d2) were in human embryonic 
stem cell (hESC) medium (Knock-out serum based) and then four days (d3-d6) in neural 
induction medium (Advanced DMEM with heparin and N-2 supplement). On the seventh 
day of differentiation (d7), EBs were gently dissociated and plated onto laminin-coated dishes 
in neural induction medium for eight days (d7-d14), resulting in a population of pre-NPCs 
(passage 1). At d15, pre-NPCs were dissociated by collagenase and replated onto laminin-
coated dishes in NPC medium (Advanced DMEM with N-2, B-27 supplement and laminin) 
containing FGF2 to promote selection and proliferation of precursor cells. The medium was 
changed every other day. Once confluent, cells were passaged 1:4 and could be cryopreserved 
in liquid nitrogen. From passage five, the cells exhibited a homogeneous morphology and 
marker profile of mature NPCs, expressing SOX2, Nestin, Vimentin, and the forebrain-specific 
NPC marker FoxG1 (figure 1b).
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figure 1. Generation and characterization of nPCs and neuronal networks from iPSCs. (a) Scheme illus-
trating the major developmental stages of the protocol for generating NPCs and neuronal networks. (b) Immu-
nostaining for NPC markers Nestin, SOX2, Vimentin and FOXG1 (scale bars=30 μm). (c) Proportion of NeuN+ 
and GFAP+ cells (days 56–70). (d) Immunostaining for glial marker GFAP, and mature neuronal markers MAP2 
and NeuN (top, scale bar=20 μm; bottom, scale bar=10 μm). (e) Co-labeling of pre- and postsynaptic marker 
proteins, Synapsin and PSD95 (scale bar=2 μm). (f) Quantification of Synapsin+, PSD95+ and double-labeled 
puncta density (n=20 neurons). EB, embryoid body; GFAP, glial fibrillary acidic protein; iPSC, induced pluripo-
tent stem cells; NPC, neural precursor cells.
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Differentiation of neural network cultures
NPCs were utilized between passages 5-11 for neural differentiation. NPCs were plated onto 
polyornithine/laminin-coated coverslips in neural differentiation medium (Neurobasal me-
dium with N-2, B27-RA) supplemented with growth factors BDNF, GDNF, db-cAMP, and 
ascorbic acid. Throughout the entire period of neural differentiation, medium was replaced 3 
times per week. During weeks 1-4, the medium was fully exchanged. From week 5 onwards, 
only half of the medium was replaced per exchange. Electrophysiological recordings and 
confocal imaging were performed at 8–10 weeks following the initiation of NPC differentia-
tion. Neurons were positive for the neuron-specific cytoskeletal marker β-III-tubulin, nuclear 
marker NeuN, dendritic marker MAP2, presynaptic marker Synapsin and postsynaptic 
marker PSD95 (figures 1d and e). Quantification of Synapsin and PSD95 puncta confirmed 
their frequent colocalization, consistent with synaptic network connectivity, of which 
~70% were glutamatergic PSD95-labeled synapses (figures 1e and f). Moreover, electron 
microscopy confirmed a classical synaptic morphology, including presynaptic vesicle pools 
and postsynaptic density (Supplementary figures 2a and b). Furthermore, the majority of 
neurons were CTIP2+, consistent with a glutamatergic lineage identity, and mutually exclusive 
of neurons exhibiting GAD67 labeling (Supplementary figure 2c). Both glutamatergic and 
GABAergic synapses were immunohistochemically confirmed by labeling for VGLUT1 and 
GAD67, respectively (Supplementary figure 2d). The proportion of immature neurons, 
mature neurons and astroglia was quantified by staining for doublecortin (DCX), NeuN and 
GFAP, respectively. Overall, NeuN+ cells constituted 15.9% of all DAPI+ nuclei, and 10.8% 
expressed the astrocyte marker GFAP. The ratio of NeuN+ (mature neurons) to GFAP+ (as-
trocytes) was 59.5 to 40.5% (figure 1c). The remaining cells were SOX2-expressing NPCs 
(59.7%) and DCX-expressing immature neurons (13.6%) (Supplementary figure 3).
We next studied the expression of cortical layer-specific markers in the differentiated 
neurons (figure 2)26,27. Subsets of neurons were positive for the transcription factor BRN2 
that is expressed in late cortical progenitors and upper layer neurons (II-IV) (figure 2a), the 
cortical-layer marker TBR1 that is expressed in deep layer neurons (V and VI) and the sub-
plate (figure 2b), FOXP2 that is expressed in layers V and VI (figure 2c), CUX1 and CUX2 
expressed in upper layer neurons (II–IV), SATB2 expressed in layers II-V, FOXG1 expressed 
in forebrain neural progenitors and widely in neurons of the developing telencephalon, and 
CTIP2 expressed in glutamatergic projection neurons from layers V and VI (figures 2d–f). 
Juxtasomal neuronal biocytin labeling demonstrated an elaborate axonal and dendritic mor-
phology. Sholl analysis was performed to quantify dendritic branching and total dendritic 
dendritic length (Supplementary figure 4).
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figure 2. Cortical layer markers in neuronal networks. Cultures were stained at day 56 following the initia-
tion of NPC differentiation for (a) BRN2 marker of late cortical progenitors and upper layer (II-IV) neurons, 
and mature dendritic marker MAP2, (b) TBR1 that is expressed by deep layer neurons (V and VI) and in the 
subplate, (c) FOXP2 expressed in deep layer (V and VI) neurons, (d) CUX1 marker of upper layer (II–IV) 
neurons and telencephalic marker FOXG1 and (e) CUX2 marker of upper layer (II–IV) neurons and SATB2 
expressed in corticocortical projection neurons from layer V and upper layers. (f) CTIP2 expression in deep 
layer glutamatergic projection neurons. NPC, neural precursor cells.
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electrophysiology results
Whole-cell patch-clamp recordings confirmed the functional maturity of the neurons, as 
suggested from the immunocytochemical stainings. Electrophysiological recordings of iPSC-
derived neurons were compared across three independent lines.
Most protocols that have been reported for neuronal differentiation of human pluripotent 
stem cells employ a semi-defined culture medium, while electrophysiological recordings are 
performed either in the same culture medium or after transferring from the culture medium 
directly into a defined artificial cerebrospinal fluid (ACSF). Importantly, the use of culture 
medium for electrophysiological recordings of neurons has previously been found to impair 
spontaneous and evoked firing of action potentials, network-level spontaneous calcium 
activity, and synaptic activity16. Notably however, those experiments involved an immediate 
switch from culture medium to ACSF, whereas a substantial acute increase in extracellular 
osmolarity (from 220 mOsm/kg in culture medium to 305 mOsm/kg in ACSF) is known to 
be highly stressful for neurons28. Therefore, we implemented a gradual transition from the 
figure 3. active and passive electrophysiological properties. (a) Representative traces from a neuron firing 
repetitive mature APs during depolarizing constant-current injections. Current steps are shown in the bottom 
panel (Vm=−75 mV). The lowest depolarizing step indicates the minimal current needed to evoke an action 
potential, and the highest step corresponds to the current at which the response frequency became saturated. 
(b) Percentage of repetitive versus nonrepetitively firing neurons. (c) Frequency–current (F-I) plot among re-
petitively firing neurons. (d–k) Active and passive membrane properties. AP parameters were calculated from 
the first evoked spike. (d) Input resistance (F = 3.65, P= 0.03), (e) resting membrane potential (F = 0.82, P= 
0.44), (f) capacitance (F = 0.18, P= 0.84), (g) AP threshold (F = 1.25, P= 0.29), (h) AP amplitude (F = 1.01, P= 
0.37), (i) AP half-width (F = 4.70, P= 0.012), (j) AP rise time (F = 1.23, P= 0.30) and (k) decay time (F = 4.62, 
P= 0.013). AP, action potential.
36 Chapter 2
culture medium to the ACSF recording medium over 25 minutes by 5 serial partial exchanges 
(see Materials and Methods section for details).
Mature APs were defined as being those which reached a membrane potential above 0 mV, 
with a fast depolarization (≤5ms rise time), and rapid repolarization (≤10ms decay time). 
Nearly all recorded cells were capable of firing mature APs in response to depolarizing current 
injections (111/114 cells, 97.4%). Among these cells, 79.3% (88/111) exhibited repetitive firing 
of mature APs (figure 3a and b), with a peak frequency of ~13 Hz (figure 3c). The remain-
ing 20.7% (23/111 neurons) fired an initial mature AP followed by a sequence of APs that 
exhibited rapid accommodation and no longer met the criteria for AP maturity.
Detailed electrophysiological measurements of intrinsic properties were performed among 
the group of neurons that were defined as mature based on their ability to fire mature APs 
repetitively in response to current injection. Passive and active membrane properties were 
quantified and compared in order to evaluate both the physiological maturity of the neurons 
and the variability between lines. The mean input resistance was 1.28 ± 0.05 GΩ (figure 
3d). Resting membrane potential was -58.2 ± 1.0 mV (figure 3e). The average capacitance 
was 49.1 ± 2.9 pF (figure 3f). AP threshold was -50.9 ± 0.5 mV (figure 3g). AP amplitude, 
measured from voltage threshold to peak, was 66.5 ± 1.3 mV (figure 3h). AP half-width was 
figure 4. Spontaneous action potentials. (a) Representative current-clamp recording from a spontaneously 
active neuron (Vm=− 68 mV). (b) Percentage of neurons with spontaneous AP firing. (c) Voltage responses 
of the same neuron in (a) to hyperpolarizing or depolarizing current injections (bottom panel), before (top 
panel) and after (middle panel) TTX application (Vm=− 75 mV). (d) Sodium currents were abolished by TTX 
(before, top panel; after, bottom panel) (Vm=− 80 mV). (e) Voltage dependence of the peak amplitude of the 
sodium current.
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3.18 ± 0.11 ms (figure 3i). AP rise and decay times were 1.9 ± 1.0 ms (figure 3j) and 3.36 ± 
0.16 ms (figure 3k), respectively.
Another important aspect of neuronal network maturity is spontaneous AP firing28-30. The 
majority of neurons exhibited spontaneous APs (59.1%, 52/88 neurons) (figure 4, a and b). 
Importantly, sustained high-quality whole-cell recordings could be maintained for more than 
30 minutes (longest recording time examined) with a stable membrane potential and AP 
waveform, confirming that the presence of spontaneous APs was not the result of poor health 
(Supplementary figure 5a). Moreover, spontaneous firing of APs was also evident in non-
permeating cell-attached recordings, thereby establishing that the presence of spontaneous 
APs was not an artifact of the whole-cell configuration (Supplementary figure 5b).
In order to confirm that the observed APs were driven by active sodium channel conduc-
tance, we blocked voltage-gated sodium channels by applying TTX to the bath solution in a 
subset of recordings. As expected, action potentials were completely abolished (figure 4c). 
Voltage-clamp recordings demonstrated the presence of fast sodium currents, as evident from 
the fast inward current observed in response to depolarized membrane potentials (figure 4, 
d [upper panel] and e). Inward voltage-gated sodium currents were also completely blocked 
by TTX (figure 4d [lower panel]).
Another important aspect of neuronal maturity is synaptic connectivity. Spontaneous syn-
aptic activity was evident in 73.8% of neurons (figure 5a-c). The frequency and amplitude of 
figure 5. neuronal network synaptic activity. (a) Representative voltage-clamp recording from a neuron with 
spontaneous synaptic input (Vm=−80 mV). (b) Zoom-in of the region in (a) marked by the red asterisk, con-
taining two postsynaptic events. (c) Percentage of neurons exhibiting spontaneous synaptic input. (d–g) Spon-
taneous postsynaptic currents: (d) frequency (F= 2.55, P= 0.09), (e) amplitude (F = 7.25, P= 0.001; post hoc 
Tukey: P=0.01 for line 1 vs 2, P=0.004 for line 2 vs 3 and P=0.52 for line 1 vs 3), (f) rise time (F = 1.24, P= 0.30) 
and (g) decay time (P= 0.023, F= 4.01).
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synaptic events was 1.09 ± 0.17 Hz (figure 5d) and 16.03 ± 0.82 pA (figure 5e), respectively. 
Line 2 exhibited significant pairwise differences in the amplitude of synaptic events compared 
to lines 1 and 3 (F=7.25, p=0.001; post-hoc Tukey: p=0.01 for line 1 vs. 2, p=0.004 for line 2 
vs. 3, p=0.52 for line 1 vs. 3). The kinetics of these events resembled those typically observed 
from neuronal recordings in acute ex vivo neocortical tissue slices, with an average rise time 
of 1.66 ± 0.65 ms (figure 5f) and decay time of 5.59 ± 0.48 ms (figure 5g). Blockade of 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-Methyl-D-aspartic 
acid (NMDA) receptors using 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 50 μM) and 
(2R)- amino-5-phosphonovaleric acid (APV, 50 μM) confirmed the dominant contribution 
of glutamatergic transmission to the synaptic network activity (Supplementary figure 6).
DISCuSSIon
We describe the results of a robust simplified protocol for neural network differentiation 
from human iPSCs with a particular focus on electrophysiological maturity. The observed 
electrophysiological maturity was achieved using a common iPSC-derived neural progenitor 
to obtain both neurons and astrocytes, and therefore obviated the need for exogenous glial cell 
co-culture. We observed a consistent 60:40 ratio of neurons-to-glia, which included neurons 
representative of both upper and deep cortical layers. The maturity of the resulting neural 
networks was further evident by reducing the volume of medium changes over the course of 
differentiation, following the rationale that the emerging neural networks become increas-
ingly self-sufficient.
This protocol requires no specialized media to obtain high-quality whole-cell patch-clamp 
recordings from iPSC-derived neurons with mature electrophysiological properties. We 
implemented a gradual equilibration procedure to transition cultures from standard neural 
differentiation medium to ACSF. The significance of the osmotic environment to the electro-
physiological properties of iPSC-derived neurons was recently demonstrated by Bardy et al., 
who introduced a specialized medium for neural cell culture and electrophysiological record-
ings16. While the use of a specialized medium was implemented by Bardy et al. to facilitate 
neuronal differentiation, we demonstrate the feasibility of using standard neural differentia-
tion media while minimizing the physiological response to acute osmotic changes through a 
gradual equilibration from culture medium to ACSF.
Electrophysiological properties define neuronal maturation. Many neuronal electrophysi-
ological parameters exhibit significant alterations over the course of neurodevelopment32–34. 
Resting membrane potential (Vm) tends to become progressively more hyperpolarized during 
neurodevelopment and stabilizes at approximately -70 mV in human neocortical ex vivo tis-
sue slices35, for which our protocol generated neurons with a comparable average Vm of -58 
mV. Input resistance also decreases throughout neurodevelopment, as a result of both a higher 
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ion channel density and a more complex cell morphology33,34. Neurons from adult human 
neocortex have an input resistance on the order of 50-150 MΩ35 while that of second trimester 
human neocortical neurons is approximately 2 GΩ32. Our protocol generated neurons with an 
average input resistance of 1.27 GΩ, consistent with a late gestational or early postnatal neu-
rodevelopmental period. As neurons mature, their AP firing threshold becomes increasingly 
hyperpolarized, and the AP waveform exhibits more rapid kinetics with larger amplitudes34,35. 
Consistent with our observed input resistance, the AP threshold and half-width are also 
comparable with neurons recorded from ex vivo human mid-to-late gestational neocortical 
tissue32.
The emergence of synaptic transmission is another defining aspect of neuronal network 
maturation which is continuously and dynamically regulated by short- and long-term forms 
of plasticity, and considered among the latest developing aspects of neuronal physiology36. 
Consistent with the estimated neurodevelopmental stage of the passive membrane proper-
ties and active AP characteristics in neurons derived using the current protocol, the synaptic 
parameters we measured are also comparable to those observed in mid-to-late gestational 
human neocortex32. But in contrast to the low variability that we observed across different 
lines regarding passive membrane and AP characteristics, synaptic properties exhibited a 
generally higher variance, although spontaneous postsynaptic current amplitude was the 
only parameter that demonstrated statistically significant differences between lines. Synapse 
formation and synaptic function develop over an extended period in neurodevelopment and 
are governed by a sizeable proportion of the genome, with ~9% of all protein-coding genes 
expressed at mammalian excitatory synapses37,38. Accordingly for iPSC-based disease model-
ing of defined genetic factors, isogenic controls may be particularly important for studies 
designed to investigate synaptic function. In contrast, AP parameters and passive membrane 
properties appear to be more robust across differing genetic backgrounds.
In summary, we have developed a reliable differentiation protocol for generating elec-
trophysiologically-mature iPSC-derived neuronal networks without the need for astrocyte 
co-culture or specialized media. Moreover, our findings provide a quantitative basis for 
considering the variability of distinct electrophysiological parameters for iPSC-based disease 
modeling. We envision this protocol to be of considerable utility for implementing cellular 
modeling approaches to the study of human neuropsychiatric disease pathogenesis.
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Supplementary figure 1. Characterization of iPSCs. iPSCs exhibit robust expression of the pluripotency 
markers NANOG, TRA181, and Oct4 (scale bars = 100µm).
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Supplementary figure 2. Synapse ultrastructure and neurotransmitter specification. (a,b) Transmission 
electron microscopy confirms a normal synaptic ultrastructure. Asterisks indicate synaptic vesicles in presynap-
tic terminals. (c) Mutually exclusive expression of GABAergic and glutamatergic markers, GAD67 and CTIP2 
respectively, in MAP2+ neurons. (d) High magnification images of VGLUT1+ and GAD67+ synaptic puncta 
(scale bars = 3µm).
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Supplementary Figure 3. 
Supplementary figure 3. Immunohistochemical markers of neuronal maturation. (a) Distribution of neu-
ronal lineage differentiation subdivided between DCX+ (immature) and NeuN+ (mature) neurons. (b) Overall 
distribution of neuronal maturation within the entire population of DAPI+ cells following NPC differentiation.
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Supplementary figure 4. neuronal morphology. (a) Representative image of a biocytin-labelled neuron (scale 
bar = 10 μm). (b) Sholl analysis of dendritic branching and total dendrite length (n = 9 neurons).
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Supplementary figure 5. extended recordings of spontaneous aPs. (a) Representative 12 min whole-cell re-
cording at resting membrane potential (Vm = -53 mV) demonstrating stable spontaneous AP fi ring. (b) Loose-
patch recording (12 min) of an independent neuron demonstrating stable spontaneous AP fi ring, confi rming 
that the patch-clamp confi guration is not responsible for the spontaneous AP activity.
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Supplementary figure 6. Pharmacological confi rmation of synaptic activity and neurotransmitter identity. 
Transient (10 min) blockade of glutamatergic AMPA and NMDA receptors through extracellular bath applica-
tion of 50 μM CNQX and 50 μM APV strongly reduced the amplitude of spontaneous postsynaptic currents, 
which returned to baseline levels upon washout (Vm = -80 mV).
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aBSTraCT
Silencing of the FMR1 gene leads to fragile X syndrome, the most common cause of inherited 
intellectual disability. To study the epigenetic modifications of the FMR1 gene during silenc-
ing in time, we used fibroblasts and induced pluripotent stem cells (iPSCs) of an unmethylated 
full mutation (uFM) individual with normal intelligence. The uFM fibroblast line carried 
an unmethylated FMR1 promoter region and expressed normal to slightly increased FMR1 
mRNA levels. The FMR1 expression in the uFM line corresponds with the increased H3 
acetylation and H3K4 methylation in combination with a reduced H3K9 methylation. After 
reprogramming, the FMR1 promoter region was methylated in all uFM iPSC clones. Two 
clones were analyzed further and showed a lack of FMR1 expression, whereas the presence 
of specific histone modifications also indicated a repressed FMR1 promoter. In conclusion, 
these findings demonstrate that the standard reprogramming procedure leads to epigenetic 
silencing of the fully mutated FMR1 gene.
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InTroDuCTIon
The most common inherited form of intellectual disability, fragile X syndrome (FXS), is 
caused by the absence of the FMR1 gene product, the fragile X mental retardation protein 
(FMRP). In the majority of FXS patients, the transcriptional silencing of the FMR1 gene is 
initiated by an expansion of a naturally occurring CGG repeat in the 5’ UTR of the FMR1 
gene, to more than 200 units1,2. This so-called full mutation results in hypermethylation of the 
cytosines in the repeat region and the FMR1 promoter region during early human embryonic 
development3,4. This results in a lack of FMR1 transcription and consequently an absence of 
FMRP. Along with hypermethylation, the FMR1 promoter in FXS is characterized by addi-
tional epigenetic marks specific for transcriptionally repressed chromatin including reduced 
histone H3 and H4 acetylation, reduced histone H3K4 methylation, and increased histone 
H3K9 methylation5-8. However, the timing and molecular mechanisms involved in the CGG 
expansion, the concomitant DNA methylation, and the additional epigenetic changes that 
occur during embryonic development are not yet fully understood.
Insights into these processes may lead to a more complete understanding of the develop-
mental processes underlying fragile X syndrome, which, in turn, could lead to new therapeutic 
strategies. Because murine fragile X models cannot be used to investigate epigenetic FMR1 
inactivation as methylation of the full mutations does not occur, human FXS embryonic stem 
cells have been studied. These studies showed that FMRP is expressed during early embryonic 
development, but that epigenetic silencing of FMR1 occurs upon differentiation9,10. A further 
attempt to study the epigenetic changes over time made use of induced pluripotent stem cells 
(iPSCs) generated from human FXS fibroblasts. In contrast to human embryonic FX stem 
cells, these pluripotent cells were shown to already carry a fully methylated FMR1 promoter 
and additional heterochromatin marks, so the epigenetic silencing mechanisms in time could 
not be studied11-13.
In 1991, a familial case was reported in which two brothers with normal intelligence were 
shown to have a full FMR1 mutation without the concomitant hypermethylation of the CGG 
repeat and the promoter region14. In order to unravel the molecular mechanisms behind the 
epigenetic silencing in fragile X syndrome, we derived iPSCs from these human fibroblasts, to 
analyze the epigenetic characteristics of the FMR1 promoter after reprogramming and during 
differentiation. Here, we report the characterization of these iPSCs and show, unexpectedly, 
that the FMR1 promoter of the unmethylated full mutation cell line becomes methylated 
during reprogramming and stays methylated after differentiation into neural progenitor cells.
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reSulTS
Fibroblast Characterization
Fibroblasts from a normal male carrying an unmethylated full mutation first described by 
Smeets et al. (1995)14 (uFM) and fibroblasts from a clinically diagnosed male fragile X syn-
drome patient (14 years old, FXS) and an unrelated unaffected male control line (3 years old, 
control) were analyzed for FMR1 5’ UTR CGG repeat length, methylation status, FMR1 ex-
pression, and the histone marks associated with the FMR1 promoter. As expected, the control 
line showed a CGG repeat length within the normal range (<55), whereas the uFM and the 
FXS line showed CGG repeat lengths in the full mutation range (approximately 233 and 380 
repeats, respectively) (figure S1). Also, as expected, the part of the FMR1 promoter analyzed 
after bisulfite conversion was not methylated in the control and the uFM cell lines, whereas in 
the FXS cell line the FMR1 promoter was methylated (figures 1a and S2 for location of the 
primers). Because the methylation status is predictive of FMR1 expression, indeed the control 
line showed normal expression levels and the uFM line showed normal to slightly increased 
FMR1 expression, whereas the FXS cell line did not express FMR1 transcripts (figure 1B). 
Additionally, bisulfite Sanger sequencing of a region of the FMR1 promoter containing 22 
CpGs was carried out, which confirmed the absence of methylation of the FMR1 promoter in 
the uFM fibroblast line (figure 1C).
Fibroblast Reprogramming and iPSC Characterization
The fibroblasts were reprogrammed to iPSC lines according to established protocols15,16. First, 
four iPSC clones were generated that showed typical characteristics of pluripotent stem cells: 
morphology similar to that of embryonic stem cells (data not shown), expression of alkaline 
phosphatase (data not shown), silencing of the multicistronic lentiviral transgene (data not 
shown), reactivation of genes indicative of pluripotency (data not shown), immunoreactivity 
for OCT4, NANOG, TRA-1-60, TRA-1-81, and SSEA4 (figure S3), propagation for a long 
time in culture (up to passage 30), and maintenance of a normal diploid karyotype (data 
not shown). All four cell lines generated embryonic bodies that, after differentiation in vitro, 
expressed markers of endoderm, mesoderm and ectoderm (figure S3). These four lines were 
extensively characterized and the results are described below. Second, we generated eight 
additional iPSC clones from the uFM fibroblast line solely in order to confirm the methyla-
tion status of the FMR1 promoter by quantitative PCR (figure 2D). These additional iPSC 
clones were generated from the uFM fibroblast line by the same methods as described, except 
this time we used naive human stem cell medium (WIS-NHSM) as defined by Gafni et al. 
(2013)17. This medium facilitates the derivation of naive pluripotent iPSCs with properties 
highly similar to mouse naive ES cells.
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Reprogramming Effects on CGG Repeat Length, FMR1 Expression, and Methylation
Analysis of the CGG repeat in the 5’ UTR of the FMR1 promoter indicated that the repeat 
length in the cell lines carrying a full mutation did not contract to levels below 200 CGGs 
during reprogramming (figure S1). The iPSC clone of the control cell line contained a CGG 
length under 55 repeats. Nonetheless, the CGG repeat length contracted slightly in the FXS 
iPSC line after reprogramming, from 380 repeats to approximately 290 repeats. In contrast, 
the repeat was expanded in the two uFM iPSC clones to approximately 330 and 380 repeats 
(figure S1). As expected, the iPSC clone of the control cell line showed FMR1 expression, in 
contrast to the FXS iPSC clone that did not show FMR1 expression. Unexpectedly, the two 
uFM iPSC clones did not express FMR1 either (figure 2a). Further analysis showed that the 
bisulfite converted FMR1 promoter region was methylated in the FXS iPSC clone as well as 
in both uFM iPSC clones, whereas the control iPSC cell line did not show any methylation 
(figure 2B). Bisulfite Sanger sequencing confirmed the methylation status of the two uFM 
iPS clones (figure 2C). The additional eight iPS clones generated from the uFM fibroblast line 
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figure 1. Methylation Status and fMr1 
expression levels in the fibroblast Cell 
lines (A) Methylation status of a region 
of the FMR1 promoter in fibroblasts 
of the male control line, fragile X line 
(FXS), and the unmethylated full muta-
tion line (uFM). Values were normal-
ized to CLK2 promoter activity first. The 
normalized exponential values were then 
presented as a percentage relative to the 
female fibroblast control line, for which 
the normalized exponential values were 
set to 50% for each primer set (n = 2–3 
separate measurements). (B) Real-time 
quantitative PCR data showing FMR1 
transcript levels in fibroblasts of the male 
control line, fragile X line (FXS), and the 
unmethylated full mutation line (uFM) 
normalized to CLK2 expression. Values 
are means ± SEM relative to appropriate 
male control line (n = 2–3 separate mea-
surements). (C) The percentage of meth-
ylated CpGs in the FMR1 promoter and 
as a control the OCT4 promoter, in 13 
and ten clones, respectively, after Sanger 
sequencing of bisulfite converted DNA of 
the uFM fibroblast line. Each line repre-
sents a clone, and each circle represents 
a CpG site, which is methylated (closed 
circle) or unmethylated (open circle). See 
also Figures S1 and S2.
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figure 2 Methylation Status and FMR1expression levels in the Induced Pluripotent Stem Cells
(a) real-time quantitative PCR data showing FMR1 transcript levels in induced pluripotent stem cells (iPSCs) 
of the male control line, fragile X line (FXS), and the unmethylated full mutation clones (uFM clone 1 and clone 
2) normalized to CLK2 expression. Values are mean ± SEM relative to appropriate male control line (n = 2–3 
separate measurements).
(B) Methylation status of a region of the FMR1promoter in iPSCs of the male control line, fragile X line (FXS), 
and the unmethylated full mutation clones (uFM clone 1 and clone 2). Values were normalized to CLK2 pro-
moter activity  first.  The normalized exponential values were then presented as a percentage relative to the 
female fibroblast control line, for which the normalized exponential values were set to 50% for each primer set 
(n = 2–3 separate measurements).
 97
in WIS-NSHM medium also showed complete methylation of the bisulfite converted FMR1 
region (figure 2D). Thus, the originally unmethylated extended CGG repeat found in the 
uFM fibroblasts became methylated at some point during the reprogramming process.
Chromatin immunoprecipitation (ChIP) experiments with the fibroblast lines showed that 
the FMR1 promoter of the control line carried active histone marks, H3 acetylation and H3K4 
dimethylation with values similar to the positive control, namely, the active gene APRT, and 
values much higher than the negative control CRYAA (crystalline), which only serves as a 
positive control for repressed genes. The inactive mark H3K9 trimethylation was not enriched 
in the control fibroblasts (figures 3a–3C). The uFM fibroblast line carried histone marks 
representative of an actively transcribed gene, namely, H3 acetylation and H3K4 methylation 
at similar levels as the control line. The inactive mark H3K9 methylation could not be detected 
in the uFM fibroblast line (figures 3a–3C). The FMR1 promoter of the FXS cell line only 
showed enrichment of the repressive mark H3K9 methylation (figures 3a–3C). ChIP analy-
sis of the FMR1 promoter in iPSCs showed enrichment of the active marks H3 acetylation and 
H3K4 methylation in the control iPSC clone, to levels higher than the positive control APRT. 
The FXS iPSCs and clone 1 of the uFM iPSCs showed an increase of the repressive mark H3K9 
methylation to values above the repressive control CRYAA, whereas enrichment of the active 
marks could not be detected in FXS iPSCs and uFM iPSC clones 1 and 2 (figures 3D–3f).
Next, we investigated the effects of differentiation into neural progenitor cells (NPCs) on 
FMR1 expression and methylation (see figure S4 for staining with marker SOX2). NPCs de-
rived from the FXS and uFM iPSCs lacked FMR1 expression and carried a methylated FMR1 
promoter. The NPCs derived from the control iPSC clone showed clear FMR1 expression 
and an unmethylated promoter region (figures 4a and 4B). These findings indicate that the 
reprogramming process leads to methylation of the expanded FMR1 CGG repeat sequence, 
which results in a stable shut down of FMR1 gene expression.
figure 2 Methylation Status and FMR1expression levels in the Induced Pluripotent Stem Cells
 (continued)
(C) The percentage of methylated CpGs in the FMR1 promoter and as a control the OCT4promoter, after Sanger 
sequencing of bisulfite converted DNA of the uFM iPSC clones. Each line represents a clone, and each circle 
represents a CpG site, which is methylated (closed circle) or unmethylated (open circle).
(D) Methylation status of a region of the FMR1promoter in additionally generated iPSC clones of the unmethyl-
ated full mutation fibroblast line in naive human stem cell medium. Values were normalized to CLK2promoter 
activity first. The normalized exponential values were then presented as a percentage relative to the female 
fibroblast control line, for which the normalized exponential values were set to 50% for each primer set (n = 2 
separate measurements). See also Figures S1–S3.
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Figure	3	
	
	
	
	
	
	
	
	
	
	
	
figure  3 Chromatin Immunoprecipitation analysis of H3 acetylation, H3k4 Methylation, and H3k9 
Methylation in the FMR1 Promoter of fibroblasts and iPSCs
Chromatin immunoprecipitation analysis of H3 acetylation, H3K4 methylation, and H3K9 methylation in 
the FMR1 promoter of fibroblasts (A–C) and iPSCs (D–F), respectively. Results were normalized to the ap-
propriate positive control (APRT or CRYAA), averaged from at least two different experiments and shown with 
their respective SEs.
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DISCuSSIon
We undertook this study in an attempt to unravel the epigenetic mechanisms involved in the 
silencing of the FMR1 gene in fragile X syndrome by the use of a fibroblast line carrying an 
unmethylated full mutation. There have been several attempts to study epigenetic silencing 
in fragile X syndrome. Eiges et al. (2007)9 have shown that FXS human embryonic stem cells 
(hESCs) still express FMRP at a level similar to that in unaffected hESCs, whereas the FMRP 
level decreases as the hESCs were differentiated. Based on these results, it was expected that 
	
	
	
Figure	4	
figure 4 Methylation Status and FMR1expression levels in neural Progenitor Cells
(A) Real-time quantitative PCR data showing FMR1 transcript levels in neural progenitor cells (NPCs) of the 
male control line, fragile X line (FXS), and the unmethylated full mutation clones (uFM clone 1 and clone 2) 
normalized to CLK2 expression. Values are mean ± SEM relative to appropriate male control line (n = 2 separate 
measurements).
(B) Methylation status of a region of the FMR1promoter in NPCs of the male control line, fragile X line (FXS), 
and the unmethylated full mutation clones (uFM clone 1 and clone 2). Values were normalized to CLK2 pro-
moter activity first. The normalized exponential values were then presented as a percentage relative to the 
female fibroblast control line, for which the normalized exponential values were set to 50% for each primer set 
(n = 2–3 separate measurements). See also Figures S2 and S4.
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by reprogramming FXS fibroblasts into pluripotent stem cells, the hypermethylated state of 
the FMR1 promoter region would be reversed. However, by now several research groups have 
shown that iPSCs derived from FXS patients show epigenetic marks characteristic for hetero-
chromatin similar to the full mutation fibroblasts they originated from11-13. These observations 
could be explained by the fact that the FXS iPSCs may not have all the characteristics of early 
pluripotency, but that they represent a later stage of human development11-13,17.
Another approach was used in studies with human fragile X lymphoblastic cells; here, a fully 
mutated and hypermethylated FMR1 gene was reactivated by treatment with 5-azadeoxycyti-
dine, a hypomethylating agent. Although such treatment significantly reduced DNA methyla-
tion in some cells, it could not restore all remaining epigenetic marks to control levels5,6,18,19. 
Drugs such as 4-phenylbutyrate, sodium butyrate or trichostatin A, which block the activity 
of histone deacetylases, did not restore FMR1 expression to normal levels5,6,8,19. In addition, 
treatment with a compound that reduces the in vitro expression of the FRAXA fragile site, 
acetyl-l-carnitine, did not restore the FMR1 expression either8. Recently, 5-azadeoxycytidine 
treatment was also tested on fragile X iPSCs, and it appeared to restore FMR1 expression 
in both iPSCs and differentiated neurons, which offers possibilities to use these cells as an 
epigenetic model13.
The availability of a fibroblast cell line carrying an unmethylated full mutation (uFM) 
provided a new opportunity to study the epigenetic silencing mechanisms in time. We first 
characterized the uFM fibroblast cell line together with a normal male fibroblast control line 
and a FXS fibroblast cell line carrying a fully methylated FMR1 promoter. Although increased 
FMR1 mRNA levels (up to five times) were reported in lymphoblastoid cells of premutation 
carriers (55~200 unmethylated CGGs), our findings of normal to slightly increased FMR1 
mRNA levels in the uFM fibroblasts are similar to the findings of Pietrobono et al. (2005)7, 
who examined a lymphoblastic cell line from the same individual. The lack of DNA methyla-
tion ensures that the chromatin is less densely packed and more accessible for transcription, 
which explains the FMR1 expression in this cell line. Our ChIP results differ from the original 
ChIP analysis of the uFM lymphoblastoid cell line8. We found a similar increase in H3K4 
methylation; however, we did not find decreased H3 acetylation levels or intermediate H3K9 
levels in the uFM fibroblasts. These differences could be explained by the fact that we have 
analyzed a distinct cell type (fibroblasts versus lymphoblastoid cells), and by differences in 
the ChIP protocol (e.g., quantification methods and reference genes used). Because the uFM 
fibroblast line lacked methylation of the FMR1 promoter site despite the high number of CGG 
repeats, we expected to find an unmethylated FMR1 promoter and normal levels of FMR1 
mRNA after reprogramming into iPSCs. Surprisingly, we found the promoter region of FMR1 
to be hypermethylated in all iPSC clones. Other epigenetic chromatin marks also indicated 
a repressed FMR1 promoter similar to the marks observed in the fragile X iPSC line. After 
differentiation of these iPSCs into neural progenitor cells, the FMR1 promoter remained 
methylated and thus silenced.
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There are three possible explanations for our findings. First, it is possible that the reprogram-
ming process resulted in iPSCs that were solely derived from methylated FM fibroblasts and 
not of the unmethylated cells. This assumes that methylated FM fibroblasts were present in 
our culture, which according to our bisulfite sequencing results seems highly unlikely. Second, 
there may be an unknown genetic factor present in this individual that was protective against 
DNA methylation during embryonic development but which was absent in his fibroblasts or 
which was altered or blocked during the reprogramming process. In our case, the brother 
of this individual was also carrier of an unmethylated full mutation. Being a carrier of an 
unmethylated full mutation is already a very rare phenomenon, but the fact that two children 
escaped methylation in one family clearly points towards the involvement of a maternal-
paternal genetic component or environmental factors. Finally, the reprogramming process 
might activate genes that induce de novo methylation of the FMR1 promoter. Although the 
FMR1 gene in this individual escaped methylation during embryonic development, the full 
mutation in his fibroblasts might be recognized by epigenetic remodelers, e.g., by histone and/
or DNA methyltransferases (DNMTs) that are not recruited in embryonic development. This 
would also explain the unmethylated full mutation observed in human embryonic FXS stem 
cells because these cells never went through this reprogramming process. A strategy to test 
this hypothesis would be, for example, to perform the reprogramming of the uFM fibroblasts 
as well as FXS fibroblast lines under conditions that inhibit the functioning of DNMT 3a and 
3b.
In conclusion, standard reprogramming of somatic uFM fibroblasts into pluripotent stem 
cells by the use of four transcription factors did not lead to demethylation of the expanded 
CGG repeat and even induced methylation of an unmethylated template. Very recently, Gafni 
et al. (2013)17 suggested that a more naive ground state pluripotent stem cell in which epigen-
etic memory is completely erased could be obtained by a unique combination of cytokines and 
small molecule inhibitors (WIS-NHS medium). Their study also demonstrated the reactiva-
tion of the FMR1 gene in FXS iPSCs after the reprogramming of FXS fibroblast under naive 
conditions. However, in contrast to these findings, the use of this WIS-NHS medium did not 
prevent the occurrence of the de novo methylation of the extended FMR1 repeat in our uFM 
iPS clones. In conclusion, our results show that although this fibroblast line may offer a unique 
system to study the de novo methylation of an extended FMR1 repeat during reprogramming, 
the mechanism behind the silencing of the FMR1 gene in fragile X syndrome remains elusive.
exPerIMenTal ProCeDureS
Cell Culture
The rare fibroblast cell line established from a normal male carrying an unmethylated full mu-
tation first described by Smeets et al. (1995)14 (uFM) was used. This line has been subcloned, 
102 Chapter 5
so that a homogenous population of cells that carry a fully extended repeat was obtained. 
Fibroblasts from a clinically diagnosed male fragile X syndrome patient (14 years, FXS), and 
an unrelated unaffected male (3 years, control) and female control fibroblast line (9 years) 
were all obtained from the cell repository of the department of Clinical Genetics, Erasmus 
MC, Rotterdam. For culture conditions, see the Supplemental Experimental Procedures.
iPSC Generation
Reprogramming of human primary skin fibroblasts was performed as described previously16. 
Briefly, fibroblasts were infected with a single, multicistronic lentiviral vector encoding OCT4, 
SOX2, KLF4, and MYC and cultured on γ-irradiated mouse embryonic feeder (MEF) cells un-
til iPSC colonies could be picked16. The second round of reprogramming of the uFM fibroblast 
line was done in naive ES medium (WIS-NHSM medium) according to Gafni et al. (2013)17 
(see the Supplemental Experimental Procedures). These cells were used to affirm the methyla-
tion status of the FMR1 promoter after reprogramming by methylation specific quantitative 
PCR. For further details, see the Supplemental Experimental Procedures.
In Vitro Differentiation of Embryonic Bodies
To form embryonic bodies (EBs), iPSC colonies from two wells per line were broken up by col-
lagenase IV treatment and transferred to ultralow attachment 6-well plates (Corning). For the 
germ layer differentiation conditions, see the Supplemental Experimental Procedures. After 2 
weeks in culture, the cells were fixed with formalin and immunostainings were performed (see 
the Supplemental Experimental Procedures).
Neural Differentiation
Human iPSCs were differentiated according to Brennand et al. (2011)20, with modifications 
(see the Supplemental Experimental Procedures). After 1 week, NPCs were dissociated with 
collagenase (100 U/ml), replated, and used for staining and methylation analysis after three 
to five passages.
Karyotype Analysis and Immunocytochemistry
Standard staining procedures were followed; for details, see Supplemental Experimental 
Procedures.
CGG Repeat Length, FMR1 Expression, and Methylation Analysis
CGG repeat size was determined in a PCR using the primers 5’- CGGAGGCGCCGCTGC-
CAGG-3’ and 5’-TGCGGGCGCTCGAGGCCCAG-3’ with the Expand high fidelity PCR kit 
(Roche) supplemented with 2.5 M betaine (see the Supplemental Experimental Procedures). 
For details of the FMR1 expression analysis, see the Supplemental Experimental Procedures. 
Genomic DNA was modified by bisulfite treatment according to the EpiTect Bisulfite Kit. 
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The diluted converted DNA was then measured using quantitative PCR with two different 
primer set designed specifically for a region of the FMR1 promoter (see figure S1 for the 
locations). One primer set contained the methylated DNA sequence and the other contained 
the unmethylated DNA sequence of a region of the FMR1 promoter after bisulfite conversion 
(see the Supplemental Experimental Procedures).
Bisulfite Sanger Sequencing
Genomic DNA (1,000 ng) was modified by bisulfite treatment according to the EpiTect 
Bisulfite Kit. Then a region of the FMR1 promoter containing 22 CpGs was amplified using 
PlatinumTaq (Invitrogen) (see figure S1 for location of the primers). PCR products were 
cloned into pGEM-T Easy (Promega), and single clones were sequenced by Sanger sequencing 
(see Supplemental Experimental Procedures).
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed according to the Upstate ChIP 
protocol with some small modifications (see Supplemental Experimental Procedures). Eluted 
DNA fragments were used for quantitative PCR analysis (see figure S1 for location of the 
primers). The Ct values of the histone modifications were first normalized for the nonspecific 
immunoglobulin G antibody treatment and then for the amount of input DNA. Data were 
then presented in relative fold enrichment after further normalization to the APRT gene for 
H3 acetylation and H3K4 methylation and CRYAA for H3K9 methylation. Data from at least 
two separate experiments were averaged, and both reference genes were previously used by 
Urbach et al. (2010)11 and Bar-Nur et al. (2012)13.
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Figure S1: Repeat length analysis before and after reprogramming into iPS cells
The male control fibroblasts and the derived control iPS cells show a repeat length below 55. The fragile
X (FXS) fibroblast line shows a repeat length of approximately 380 repeats. The derived FXS iPSCs
show a small contraction of the repeat length to approximately 290 repeats. The unmethylated full
mutation (uFM) fibroblast line has a repeat length of approximately 233 repeats (~750bp). The two uFM
iPS cell clones show an expanded repeat length of approximately 380 (clone 1) and 330 repeats (clone 2).
A DNA sample containing 98CGG repeats was run on the same gel, in addition to a water control. All 
products of the CGG repeat PCR were run on one agarose gel with a ladder on both sides. A band at the
marker level of 650 base pairs corresponds with a CGG repeat length of 200 repeats.
to Figures 1 and 2
figure S1: repeat length analysis before and aft er reprogramming into iPS cells
Th e male control fi broblasts and the derived control iPS cells show a repeat length below 55. Th e fragile X (FXS) 
fi broblast line shows a repeat length of approximately 380 repeats. Th e derived FXS iPSCs show a smal  contrac-
tion of the repeat length to approximately 290 repeats. Th e unmethylated full mutation (uFM) fi broblast line has 
a repeat length of approximately 233 repeats (~750bp). Th e two uFM iPS cell clones show an expanded repeat 
length of approximately 380 (clone 1) and 330 repeats (clone 2). A DNA sample containing 98 CGG repeats 
was run on the same gel, in addition to a water control. All products of the CGG repeat PCR were run on one 
agarose gel with a ladder n both sides. A band at the marker level of 650 base pairs corresponds with a CGG 
repeat length of 200 repeats. Related to Figures 1 and 2.
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13261  ccactccacc  tcccgctcag  tcagactgcg  ctactttgaa  ccggaccaaa ccaaaccaaa 
ChIP F ----------> F1 ----------> <----------- 
13381   gggataaccg  gatgcatttg  atttcccacg  ccactgagtg  cacctctgca gaaatgggcg 
<-ChIP R BSM F ---- > 
13441 ttctggccct cgcgaggcag tgcgacctgt caccgccctt cagccttccc gccctccacc 
< --- BSM R 
13501 aagcccgcgc acgcccggcc cgcgcgtctg tctttcgacc cggcaccccg gccggttccc 
< ----------- R1 
13561 agcagcgcgc atgcgcgcgc tcccaggcca cttgaagaga gagggcgggg ccgaggggct 
BSNM F --- > 
13621 gagcccgcgg ggggagggaa cagcgttgat cacgtgacgt ggtttcagtg tttacacccg 
Start of transcription 
13681 cagcgggccg ggggttcggc ctcagtcagg cgctcagctc cgtttcggtt tcacttccgg 
< --- BSNM R 
13741 tggagggccg cctctgagcg ggcggcgggc cgacggcgag cgcgggcggc ggcggtgacg 
CGG-repeat 
13801 gaggcgccgc tgccaggggg cgtgcggcag cgcggcggcg gcggcggcgg cggcggcggc 
 
13861  ggaggcggcg  gcggcggcgg  cggcggcggc  ggctgggcct  cgagcgcccg cagcccacct 
Start of translation 
13921   ctcgggggcg  ggctcccggc  gctagcaggg  ctgaagagaa  gatggaggag ctggtggtgg 
start of intron 1 
13981 aagtgcgggg ctccaatggc gctttctaca aggtacttgg ctctagggca ggccccatct 
 
Figure S2: The promoter region of the FMR1 gene with the location of the primers used in this 
study 
Sequence numbering from GenBank L29074. Primers used in this study are indicated by the 
underlined sequence in combination with the name and arrow above the sequence. Individual 
cytosines belonging to methylation sites are indicated in bold as well as the CGG-repeat. In addition, 
the start of transcription, translation and intron 1 are indicated as well. For the methylation-specific 
qPCR we analysed 11 methylation sites using the methylation specific primers (BSMF and R) and 
15 sites with the unmethylated primers set (BSNMF and R). Bisulfite sequencing by using the F1 
and R1 primers was based on Pietrobono et al, 2002, and contained 22 methylation sites. Related to 
Figures 1, 2, and 4. 
figure S2: Th e promoter region of the FMR1 gene with the location of the primers used in this study
Sequence numbering from GenBank L29074. Primers used in this study are indicated by the underlined se-
quence in combination with the name and arrow above the sequence. Individual cytosines belonging to meth-
ylation sit s are indicated in bold as well as the CGG repeat. In ad ition, the start of tra scription, translation 
and intron 1 are indicated as well. For the met ylatio -specifi c qPCR we analys d 11 methylation sites using 
the methylation specifi c pri ers (BSM F and R) and 15 sites with the unmethylated primers set (BSNM F and 
R). Bisulfi te sequencing by using the F1 and R1 primers was based on Pietrobono et al, 2002, and contained 22 
methylation sites. Related to Figures 1, 2, and 4.
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Figure S3: Expression of pluripotency markers by iPSCs and germ layer marker expression after 
in vitro differentiation 
From left to right and top to bottom you can see images showing OCT4, NANOG, Tra-1-60, Tra-1-80 
and SSEA4 expression as well as expression of the mesodermal marker smooth muscle actin (SMA), the 
ectodermal marker Tuj1 (or B-tubulin III) and endodermal marker alpha fetoprotein (AFP) (all in red) in 
the control line (A), fragile X cell line (B) and the uFM clones (C and D, clone 1 and clone 2 
respectively). For each pluripotency marker a nuclear Hoechst staining is displayed in blue. Scale bars: 
50 μm for the pluripotency markers and 100μm for the germ layer markers. Related to Figure 2. 
figure S3: expression of pluripotency markers by iPSCs and germ layer marker expression after in vitro 
differentiation
From left to right and top to bottom you can see images showing OCT4, NANOG, Tra-1-60, Tra-1-80 and 
SSEA4 expression as well as expression of the mesodermal marker smooth muscle actin (SMA), the ectodermal 
marker Tuj1 (or B-tubulin III) and endodermal marker alpha fetoprotein (AFP) (all in red) in the control line 
(A), fragile X cell line (B) and the uFM clones (C and D, clone 1 and clone 2 respectively). For each pluripotency 
marker a nuclear Hoechst staining is displayed in blue. Scale bars: 50 μm for the pluripotency markers and 100 
μm for the germ layer markers. Related to Figure 2.
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Figure S4: SOX2 expression by neural progenitor cells 
Expression of SOX2 in red by neural progenitor cells of the control line (A), fragile X cell line (B) and 
the uFM clones (C and D, clone 1 and clone 2 respectively). In each image a nuclear DAPI staining 
(in blue) is displayed as well. Scale bar 100 μm. Related to Figure 4. 
  
  
figure S4: Sox2 expression by neural proge itor cells
Expression of SOX2 in red by neural progenitor cells of the control line (a), fragile X cell line (B) and the uFM 
clones (C and D, clone 1 and clon  2 respectively). In each image a nuclear DAPI staining (i  blue) is display d 
as well. Scale bar 100 μm. Related to Figure 4.
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SuPPleMenTal exPerIMenTal ProCeDureS Cell CulTure 
ConDITIonS
The fibroblasts were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (Gibco-
Invitrogen) containing 10% fetal calf serum and 1% penicillin/streptomycin.
The first set of generated iPS cell lines, namely the male control line, the FXS line and the 
uFM iPS clone 1 and 2 were cultured in conventional ES cell culture medium containing 
DMEM/F12 (Gibco-Invitrogen) supplemented with 20% knock-out serum replacement 
(Gibco-Invitrogen), 2 mM L-glutamine, 50 units of penicillin/streptomycin/glutamine, 0.1 
mM MEM-non-essential aminoacids (PAA Laboratories GmbH), 0.1 mM B-mercaptoetha-
nol, and 10 ng/ml bFGF (Invitrogen) filtered through a 0.22 μm filter (Corning). Human iPS 
lines growing on conventional medium were passaged weekly using collagenase IV (1 mg/ml, 
Invitrogen) on γ-irradiated MEFs.
The second round of iPS cells were grown in WIS-NHSM medium containing 475 ml 
knockout DMEM (Invitrogen), 20% knockout serum (invitrogen), human insulin (Sigma, 
12.5 μg/ml), 10 μg recombinant human Lif (Peprotech), 8 ng/ml recombinant bFGF (Pe-
protech) and 1 ng/ml recombinant TGF-β1 (Peprotech), 1 mM glutamine (Invitrogen), 1% 
MEM-non-essential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), Penicil-
lin-Streptomycin (Invitrogen) and small molecule inhibitors: PD0325901 (1 μM, ERK1/2i, 
Axon Medchem); CHIR99021 (3 μM, GSK3i, Axon Medchem); SP600125 (10 μM, JNKi, 
TORCIS) and SB203580 (10 μM, p38i, Axon Medchem) Y-27632 (5 μM, Axon Medchem) 
and protein kinase C inhibitor G06983 (5 μM, TOCRIS). Naive human iPS clones were grown 
on y-irradiated MEFs on gelatin-coated plates and passaged by single-cell trypsinization 
(0.05% EDTA) every 4 days. These naive cells also showed the main characteristics of induced 
pluripotent stem cells including morphology similar to that of embryonic stem cells, silencing 
of retroviral transgenes and reactivation of pluripotency genes (data not shown).
In vitro differentiation of embryonic bodies
Floating EBs were cultured in iPSC medium without bFGF for a minimum of 6 days with 
supplemented SB431542 for ectoderm conditions only. The embryonic bodies (EBs) desig-
nated for endoderm were then transferred to gelatin coated 12-wells plates containing the 
following medium: RPMI 1640 (Gibco-Invitrogen), supplemented with 20% FBS, 1: 100 
dilution of penicillin/streptomycin/glutamine and alpha-thioglycerol (0.4mM). Mesoderm 
differentiation from the EBs was inducted in gelatin-coated 12-wells plates with DMEM low 
glucose medium supplemented with 15% FBS, 1:100 dilution of penicillin/streptomycin/glu-
tamine and 1:100 dilution of MEM-non-essential amino acids. The formation of ectoderm was 
induced in matrigel-coated plates with the following medium: neurobasal medium (Gibco) 
and DMEM/F12 (v/v 50/50) supplemented with 1:100 dilution of penicillin/streptomycin/
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glutamine and 1:100 dilution of MEM-non-essential aminoacids, 0.02% BSA (Gibco), 1:200 
N2 (Gibco) and 1:100 B27 (Gibco).
neural differentiation
Briefly, iPS colonies were dissociated from MEFs with collagenase (100 U/ml) and transferred 
to non-adherent plates in hES cell medium on a shaker in an incubator at 37ºC/5% CO2. 
After two days, embryonic bodies (EBs) were placed in neural induction medium (DMEM/
F12, 1x N2, 2 μg/ml heparin, penicillin/streptomycin) and cultured for another four days 
in suspension. EBs were gently dissociated and plated onto laminin-coated dishes in NPC 
medium (DMEM/F12, 1x N2, 1x B27-RA, 1 μg/ml laminin and 20 ng/ml FGF2, penicillin/
streptomycin). All cell culture reagents were obtained from Invitrogen.
karyotype analysis
For karyotype analysis, cells in a well of a 6-wells plate were treated with colcemid (100 ng/ml) 
for 1 hour. Then cells were harvested with trypsin, treated with hypotonic solution and fixed. 
Metaphases were spread onto glass slides and stained with DAPI (Dako). Chromosomes were 
classified according to the International System for Human Cytogenetic Nomenclature. At 
least 10 metaphases were analyzed per cell line.
Immunocytochemistry and antibodies used in this study
iPS cells or NPCs were washed with PBS once, fixed with 4% formalin solution for 5 min and 
washed again with PBS. Cells were then incubated with 50 mM glycine for 5 min, washed with 
PBS and permeabilized with 0.5% Triton X-100 for 5 min (only for OCT4 and NANOG). After 
blocking for 45 min at room temperature with 0.1% PBS-Tween containing 2% fetal bovine 
serum (Invitrogen), primary antibody staining was performed for 1 hour in room temperature 
with antibodies diluted in blocking solution. Cells were then washed and incubated with the 
appropriate secondary Cy3 or Alexa Fluor A555 antibody (1:200, Jackson Immunoresearch 
Laboratories or Invitrogen) for 45 min. Afterwards, cells were washed with twice 0.1% PBS-
Tween, with a nuclear staining step in between (Hoechst or DAPI). Cells were covered with 
Mowiol and a glass slide. Staining for alkaline phosphatase was carried out using the Alkaline 
Phosphatase kit (Sigma-Aldrich) according to the manufacturer’s instructions. The antibodies 
used for pluripotency stainings or neural marker stainings were goat anti-human OCT3/4 
(1:100, Santa Cruz Biotechnology), goat anti-human NANOG (1:50, R&D Systems), mouse 
anti-human TRA-1-60, TRA-1-80, and SSEA4 (1:100 Santa Cruz Biotechnology) and rabbit 
anti-SOX2 (1:1000 Millipore). Antibodies used for in vitro differentiation stainings were anti-
human smooth muscle actin (SMA, 1:50, DAKO), rabbit anti-human alpha-fetoprotein (AFP, 
1:200, Dako), mouse anti-human β-tubulin III (TujI) (1:200, Sigma-Aldrich).
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CGG repeat length, FMR1 expression and methylation analysis
CGG length PCr
In order to isolate total genomic DNA, cell were treated with lysis buffer containing 100 mM 
NaCl, 10 mM Tris, 15 mM EDTA, 0,5% SDS, and 5% Proteinase K. After overnight incubation 
at 55°C, DNA was extracted and precipitated using a standard protocol containing saturated 
salt solution and ethanol. PCR was performed with 35 cycles of 35 seconds denaturing at 
98°C, 35 seconds of annealing at 55°C, and 5 minutes elongation at 72°C. PCR products were 
analyzed with standard agarose gel electrophoresis.
FMR1 expression
RNA was isolated using the RNAeasy kit (Qiagen), and 1 μg of RNA was reverse transcribed 
using iScript (BioRad). Real-time PCR was carried out in triplicate using Kappa mix and a 
7300 Real-time PCR system (Applied Biosystems). A forward primer located in exon 4 was 
used in combination with a reverse primer located in exon 5 to measure FMR1 expression: 
5’-GGTGGTTAGCTAAAGTGAGGA-3’ and 5’-GTGGCAGGTTTGTTGGGATTA-3’.
CLK2 was used as reference gene with forward primer 5’-CCTACAACCTAGAGA-
AGAAGCGAG-3’ and reverse primer 5’-CACTGCCAAAGTCTACCACC-3’(de Brouwer et 
al. 2006). FMR1 expression was normalized to CLK2 expression and data was presented as 
an average value from 2 to 3 independent measurements. The expression values of the male 
control and the female control cell lines were combined and their average relative fold enrich-
ment was set to 100%.
FMR1 methylation analysis
The primers for the methylated sequence are F 5’-GGTCGAAAGATAGACGCGC-3’, R 
5’-AAACAATGCGACCTATCACCG-3’; and for the unmethylated sequence are F 5’- TGTT-
GGTTTGTTGTTTGTTTAGA-3’, R 5’-AACATAATTTCAATATTTACACCC-3’ and for 
the promoter of the unmethylated bisulfite converted reference gene CLK2: F 5’-CGGTT-
GATTTTGGGTGAAGT-3’ and R 5’-TCCCGACTAAAATCCCACAA-3’. All reactions were 
carried out in triplicate using SYBR Green ROX mix and a 7300 Real-time PCR system. Ex-
periments were only analyzed when the Ct values of the female control sample were under 30 
for both primer sets, as an indication for an efficient bisulfite conversion and DNA recovery. 
For each sample, the values for the methylated and the unmethylated sequences were normal-
ized to CLK2 promoter activity first to obtain delta Cts. The normalized exponential values 
from the measurements of both primers sets were then set to 50% for the female control cell 
line. These values represent the random X-inactivation in female control cells. The normalized 
exponential data of the remaining samples was then presented as a percentage relative to the 
female control data. Average ratios from at least two independent measurements were used 
for each sample.
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Bisulfite Sanger sequencing
The following primers were used FMR1 F1 5’-GAGTGTATTTTTGTAGAAATGGG-3’ and 
R1 5’-TCTCTCTTCAAATAACCTAAAAAC-3’ (see supplemental figure 1 for location of 
primers), while the OCT4 promoter containing 10 CpG sites was amplified using the for-
ward primer 5’-GAGGGAGAGAGGGGTTGAGTAG-3’ and the reverse primer 5’-CCTC-
CAAAAAAACCTTAAAAACTTAAC-3’ (based on Al-khtib et al. 2012).
Chromatin immunoprecipitation assay
In short, approximately 2.5 million cells were crosslinked with 1% formaldehyde for 5 minutes 
at room temperature. After quenching the reaction with 125 mM glycine, cells were subse-
quently suspended in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1) containing 
proteinase inhibitor (Roche, Complete). Chromatin was then sonicated using the Bioruptor 
(Diagonide) to create 200bp-1000bp DNA fragments. All chromatin was pre-cleared by treat-
ment with salmon sperm agarose beads (Millipore) for 0.5 hour at room temperature. Immu-
noprecipitation was performed overnight using 7.5 μg anti-acetylated histone H3 (Millipore), 
anti-dimethyl histone H3K4 (Millipore), anti-trimethyl histone H3K9 (Millipore), or anti-IgG 
antibody (Millipore) in dilution buffer. Next, crosslinking was reversed by incubation with 
0.2M NaCl at 65ºC and DNA was purified using a PCR clean-up kit (Mobio). Quantitative 
PCR analysis was carried out using primers for the FMR1 promoter region F 5’-AACT-
GGGATAACCGGATGCAT-3’ and R 5’- GGCCAGAACGCCCATTTC-3’ (see supplemental 
figure 1 for location) as well as appropriate positive and negative controls namely APRT F 
5’-GCCTTGACTCGCACTTTT-3’, and R 5’- TAGGCGCCATCGATTTTA-3’ and CRYAA F 
5’-CCGTGGTACCAAAGCTGA-3’, and R 5’-AGCCGGCTGGGGTAGAA-3’.
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aBSTraCT
Non-coding RNAs have been widely recognized as essential mediators of gene regulation. 
However, in contrast to protein-coding genes, much less is known about the influence of 
non-coding RNAs on human diseases. Here we examined the association of genetic vari-
ants located in primary microRNA sequences and long non-coding RNAs (lncRNAs) with 
Alzheimer’s disease (AD) by leveraging data from the largest genome-wide association meta-
analysis of late-onset AD. Variants annotated to five miRNAs and ten lncRNAs (in 7 distinct 
loci) exceeded the Bonferroni-corrected significance threshold (p-value <1.02×10-6). Among 
these, a leading variant (rs2526377:A>G) at the 17q22 locus annotated to two non-coding 
RNAs (MIR142 and BZRAP1-AS) was significantly associated with a reduced risk of AD and 
fulfilled predefined criteria for being functional. Our functional genomic analyses revealed 
that rs2526377 affects the promoter activity and decreases the expression of miR-142. More-
over, differential expression analysis by RNA-Seq in human iPSC-derived neural progenitor 
cells and the hippocampus of miR-142 knockout mice demonstrated multiple target genes of 
miR-142 in the brain that are likely to be involved in the inflammatory and neurodegenerative 
manifestations of AD. These include TGFBR1 and PICALM, of which their derepression in the 
brain due to reduced expression levels of miR-142-3p may reduce risk of AD.
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InTroDuCTIon
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease 
worldwide manifested by the progressive loss of memory and cognitive decline1 . Enormous 
efforts have been made over the past decades to discover risk factors for developing AD and 
to identify biomarkers for early diagnosis of the disease2-4. The determinants of early-onset 
AD have been primarily associated with mutations in one of three genes: APP, PSEN1 and 
PSEN25. In contrast, late-onset AD (after 65 years of age), the most common form of AD with 
a heritability of 60-80%, is a genetically heterogeneous disease6 . In addition to apolipoprotein 
E (APOE) polymorphisms that explain ~25% of the heritability, more than 30 genetic loci have 
so far been established as contributing to late-onset AD risk7,8. However, they explain only a 
fraction of the estimated heritability and the genetics of AD are yet to be fully understood9. To 
fully grasp the contribution of genetic factors to AD, we must go beyond classical genetics, and 
explore the multiple interacting layers that regulate the genome. This includes the analysis of 
not only the protein-coding sequences, but the vast non-coding regions as well.
Recent developments in omics technologies have revealed the complexity of the human ge-
nome, displaying that protein-coding RNAs constitute only ~2% of the human transcriptome, 
highlighting the distinct possibility that non-coding RNAs (ncRNAs) might meaningfully 
contribute to human disease10,11. Non-coding RNAs are functional RNA molecules that are 
transcribed from DNA but not translated into proteins. They are frequently categorized, on 
the basis of transcript size, as small (less than 200 nucleotides (nt)) or long non-coding RNAs 
(over 200 nt). Among these, microRNAs (miRNAs), with approximately 21-23 nt in length, 
are currently the best-characterized ncRNAs. Many studies have shown the crucial role of 
miRNAs in neurodevelopmental regulation and disease-related neuropathology including 
AD12,13. Long non-coding RNAs (lncRNAs) comprise a large and diverse class of transcribed 
RNA molecules that are classified into different subtypes (e.g., antisense and intergenic) 
according to the position and direction of transcription with regard to other genes14. It has 
become increasingly evident that lncRNAs impact disease pathogenesis primarily through 
post-transcriptional regulation of gene expression15. Despite constituting the majority of non-
coding transcriptome, few lncRNAs most notably BACE1-AS and BC200 have been so far 
characterized to play a role in the pathogenesis of AD to date16,17.
In the present study, we conducted a genome-wide scan to identify miRNAs and lncRNAs 
associated with AD by leveraging data from the largest available GWAS of late-onset AD7. 
We found several ncRNA loci significantly associated with AD, including a newly identified 
susceptibility locus on 17q22. We performed various in silico and in vitro studies to determine 
the functionality of ncRNA variant in this locus and to gain insight into the role of associated 
ncRNA in AD pathogenesis.
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MaTerIalS anD MeTHoDS
Genome-wide association study on aD
Summary statistics data were retrieved from a recent large-scale GWAS meta-analysis of late-
onset AD including 455,258 individuals of European ancestry, meta-analyzed in three phases7. 
Phase 1 consisted of 24,087 clinically diagnosed late-onset AD cases and 55,058 controls of 
European ancestry, which are collected by 3 independent consortia (Alzheimer disease work-
ing group of the Psychiatric Genomics Consortium (PGC-ALZ), the International Genomics 
of Alzheimer Project (IGAP), and the Alzheimer Disease Sequencing Project (ADSP)), and 
investigating 9,862,738 genetic variants. Phase 2 consisted of 376,113 individuals of European 
ancestry from the UK Biobank with parental AD status available (N proxy cases = 47,793; N 
proxy controls = 328,320). Phase 3 was the meta-analysis of phase 1 and 2, including 71,880 
(proxy) AD cases and 383,378 (proxy) controls. More details about the consortia and par-
ticipants are described elsewhere7. All participating studies in the AD GWAS had provided 
informed consent for participation in genetics studies and were approved by their local ethical 
committees.
Genetic variants in non-coding rnas
Genetic variants in human lncRNA transcripts were extracted using lncRNASNP, a compre-
hensive database including 495,729 SNPs in 32,108 lncRNA transcripts of 17,436 lncRNAs18. 
Moreover, as primary transcript of miRNAs has been suggested to be 3-4kb in length19, we 
used dbSNP database (https://www.ncbi.nlm.nih.gov/SNP/) to extract 16,178 SNPs located 
in +/-2kb of 1,318 mature miRNA sequences reported in miRBase v21 (http://www.mirbase.
org/). We excluded SNPs with minor allele frequency (MAF) < 0.01. Of the remaining SNPs, 
we analyzed the association with AD of 96,950 SNPs in 14,790 lncRNA transcripts and 12,404 
SNPs in 1,237 primary miRNA transcripts that were present in the GWAS summary statistics 
data7. To obtain the number of independent SNPs, we used the LD based SNP pruning in 
PLINK (http://pngu.mgh.harvard. edu/~purcell/plink/), where we excluded the SNPs with R2 
> 0.7. The Bonferroni correction was used to adjust p-value for the number of tests (0.05/49,323 
independent SNPs) and the significance threshold was set at 1.02×0-6. Regional plots showing 
the association of ncRNA SNPs and flanking variants in the corresponding loci with AD were 
generated by the LocusZoom web tool20.
assessing biological functionality of non-coding rna variants
For the ncRNA SNPs associated with AD, the LD region (R2 > 0.7) was determined using 
the 1000 Genomes Phase 3. We investigated whether known protein-coding variants were 
in strong LD with the associated ncRNA SNPs. Further, we examined whether the associ-
ated SNPs in ncRNAs are annotated to regulatory features, including promoter and enhancer 
regulatory motifs, DNase footprinting sites and conserved sequences using HaploReg (v4.1)21. 
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For each set of variants in strong LD with a given ncRNA SNP, we also investigated whether 
the SNP was located in a potential regulatory region using the Roadmap consortium reference 
epigenomes dataset22. To test the association of ncRNA SNPs with gene expression, we used 
expression quantitative trait loci (eQTL) data provided by GTEx (https://www.gtexportal.
org/home/) and BBMRI-NL atlas (http://atlas.bbmrirp3-lumc. surf-hosted.nl/#query)23. The 
UCSC genome browser was used for visualization of the ncRNA SNP location in the genome. 
The ncRNA secondary structure and the effect of a SNP on the minimum free energy (MFE) 
of the predicted ncRNA structure were investigated using the Vienna RNA Package 2.024.
Plasmids, mirna promoter constructs and cell culture transfection
To compare the activity of miR-142 promoter containing either rs2526377 alleles, the full-
length 589-bp fragment corresponding to the upstream region of the pri-miR-142 transcript 
was synthesized by Integrated DNA Technologies (IDT) and cloned into pGreenFire-CMV-
EF1-puro (System Biosciences) digested with EcoR I and Spe I. DNA sequencing verified all 
constructs. HEK293 cells were then used to generate the lentivirus with co-transfection of 
reporter gene vectors, HIV gag-pol and VSV-G in a ratio of 1:0.8:0.2. For transduction assay, 
cells were seeded into 24-well plates and transduced with lentiviral particles. With selection 
by puromycin at a concentration of 2 ug/ml, cells were calculated and seeded into 96-well. 
After incubation for 24-hours, the cell supernatant was harvested and the luciferase activity 
was then measured on a luminometer (LB960; Berthold) using the Dual-Luciferase Reporter 
Assay System (Promega). The ratio of firefly luciferase to Renilla luciferase was calculated for 
each well. The experiments were performed five times.
Quantitative rT-PCr
Total RNA from human induced pluripotent stem cell (iPSC)-derived neural progenitor cells 
(NPCs) and human brain cryopreserved sections was isolated using Trizol LS reagent (Invi-
trogen, Carlsbad, CA, USA) according to the manufacturer’s protocols. The concentration 
of total RNA was determined using a NanoDrop ND-1000 spectrophotometer (NanoDrop, 
Wilmington, DE). TaqMan qPCR Assays were performed according to the manufacturer’s 
protocols (Applied Biosystems, Foster City, CA, USA) to determine the expression levels of 
miR-142-3p, miR-142-5p, and BZRAP1-AS1. The assays were run using Applied Biosystems 
7900HT Real-Time PCR system. RNU6B was used as an internal control for miRNA expres-
sion analysis. All the experiments were performed in triplicates. The human frozen brain 
tissues (n=3 gray matter and n=3 white matter) were obtained from the Netherlands Brain 
Bank (Amsterdam, the Netherlands). All samples were free of neurological disease.
Putative target genes of mir-142
TargetScan V7.1 (http://www.targetscan.org/)25 was used to identify the putative targets of 
miR-142-3p and -5p in human and mouse. This program predicts biological targets of miR-
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NAs by searching for conserved 7/8-mer sites that match the miRNA seed region. The predic-
tions are ranked based on the putative efficacy of targeting as calculated using context scores 
of the sites, the higher context score, the greater the probability that a miRNA could target 
a particular gene. For our analysis, we used the predicted targets that had a recommended 
context score < -0.01. Further, we retrieved the list of putative target genes of miR-142 (3p and 
5p) from two other widely used online miRNA target prediction databases, miRtarget226 and 
DIANA-microT27. Then, RNA-Seq data from the Human Body Map 2.028 was used to check 
which of the miR-142 putative target genes are expressed in the human brain (Fragments Per 
Kilobase Million, FPKM ≥ 1), target genes not expressed in the brain were excluded.
Pathway analysis was performed using KEGG and IPA databases. KEGG incorporates 
knowledge of known gene networks and identifies significantly enrichment of miRNA puta-
tive targets in these networks according to a t-test29. IPA is a knowledge database generated 
from peer-reviewed scientific publications that enables the discovery of highly represented 
biological mechanisms, pathways or functions most relevant to the genes of interest from 
large, quantitative datasets. We uploaded the list of the miR-142 target genes and performed a 
core analysis with the default settings in IPA. We mapped the miRNA target genes to biologi-
cal functions or canonical pathways to see whether they are enriched in specific networks. The 
p-values are calculated using the right-tailed Fisher Exact Test and a p-value of less than 0.05 
indicates a statistically significant, nonrandom association.
rna-Seq analysis in human iPSC-derived neural progenitor cells (nPCs)
NPCs derived from human control iPSCs (Sigma-Aldrich line iPSC0028) were cultured to 
70% confluency in 6-well plates (Corning) according to standard protocols30. NPCs were 
transfected with 10 nM miRNA mimics (mirVanaTM Mimics, Thermo Fisher Scientific) in-
cluding miR-142-3p, miR-142-5p, and the standard negative control #1 (Catalog nr. 4464060), 
or without any mimic (untreated). Transfections were performed using X-treme GENETM 
transfection reagent (Merck) according to manufacturer’s instructions. The experiment was 
run in triplicate. Total RNA was isolated 72 hours after transfection from the four groups 
of NPC samples using the RNeasy mini kit (Qiagen, 74104). The RNA quality was checked 
by Agilent’s 2100 Bioanalyzer (using Eukaryote Total RNA Nano kit). RNA-Seq analysis was 
performed at Erasmus MC Center for Biomics to test the changes in gene expression pattern 
in NPCs after overexpression of either miR-142-3p or -5p compared to controls.
rna-Seq analysis in the hippocampus of mir-142 ko mice and wt littermates
MiR-142 in mice is located on chromosome 11 and in the vicinity of the second exon belong-
ing to Mir142hg (ENSMUSG00000084796). The miR-142-/- knockout mouse is a model with 
complete deletion of miR-142, with a significant decrease in the expression levels of both 
miR-142-3p and -5p isoforms31. The expression of Bzrap1, a gene immediately flanking miR-
142 is not altered in the miR-142-null mice, while the expression of a long non-coding RNA 
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(Mir142hg) embedded within the miR-142 gene is decreased. We confirmed the homo- and 
heterozygosity of miR-142 KO mice by qPCR. The hippocampi of miR-142-/- , miR-142-/+ and 
miR-142+/+ littermates (n=4 for each group, age 13-14 weeks, gender balanced in all groups) 
were collected and total RNA was extracted using the RNeasy lipid tissue kit (Qiagen, 74804). 
RNA quality was checked by Agilent’s 2100 Bioanalyzer (using Eukaryote Total RNA Nano 
kit). RNA-Seq analysis was performed at Erasmus MC Center for Biomics to identify target 
genes of mmu-miR-142a-3p and mmu-miR-142a-5p that are differentially expressed in the 
hippocampus samples of mice in the different groups. Animal experiments were approved 
by the Federal Authorities of Animal Research of the Regierungspräsidium Giessen, Hessen, 
Germany (Approved Protocol No. 613_M).
Data analysis and statistics
The nonparametric Mann–Whitney test was used to compare miR-142 expression between 
the genotype groups, and an unpaired/independent t-test was used to compare reporter gene 
activities. In vitro experiments were repeated at least three times and histograms represent 
mean ±S.D. Statistical differences were measured using unpaired two-sided Student’s t-test. 
P < 0.05 was considered as statistically significant. Data analysis was performed using Excel 
Software Version 14.4.5.
RNA-Seq was performed with the Illumina TruSeq Stranded mRNA Library prep kit. The 
resulting DNA libraries were sequenced on the HiSeq2500, for single-end reads of 50bp length. 
Reads were generated of 50 base-pairs in length. Reads were mapped against the GRCm38 
reference genome using HiSat2 (version 2.0.4)32. We called gene expression values (reads per 
gene) using htseq-count (version 0.6.1)33. We took only expressed genes into account, genes 
with at least 5 reads in at least 7 samples (half of the samples plus one). This filtering in iPSC-
derived NPCs resulted in 17,181 genes. Differential expression analysis of the RNA–Seq data 
in human iPSC-derived NPCs was performed using R (version 3.3.2) and DESeq2 (version 
1.14.1)34-36. Briefly, DESeq2 generated three values for each gene that were used for subsequent 
analysis: 1. Log2 fold change (Log2FC), 2. p-value based on the Wald test, and 3. Corrected 
p-value controlling the false discovery rate to 5%. Genes were considered differentially ex-
pressed if the corrected p-value was lower than 0.05. For the biological interpretation of the 
results, we placed an additional cut-off of fold change ≥ 1.2.
reSulTS
non-coding rnas associated with aD
In total, we examined the associations of 108,862 unique SNPs in primary miRNA sequences 
and lncRNAs with AD. Of these, SNPs annotated to 5 miRNAs and 10 lncRNAs, located in 7 
distinct loci (each locus defined as 1 Mb), exceeded the significance threshold (p-value < 1.02 
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×10-6) (Table 1). We assessed whether the associated ncRNA SNPs are likely to be functional 
in their corresponding loci based on a set of criteria recommended by previous studies to 
assess the potential functionality of ncRNA SNPs in GWAS results37,38. These criteria include 
an established association between SNP and the trait, the correlation of SNP with expression 
of the host ncRNA, the localization of SNP in the ncRNA regulatory regions and the potential 
of SNP for structural perturbations in the host ncRNA.
As shown in the regional association plots (Supp.figure S1), in 6 of the 7 identified non-
coding RNA loci were coding variants in strong LD (R2 > 0.7) with the ncRNA SNPs more 
significantly associated with AD (Supp.Table S1), which complicating interpretations of the 
coding versus non-coding variants in these loci. In contrast, in the 17q22 locus, the top-
associated variant (rs2526377:A>G, chr17:58332680) localized in two ncRNAs, MIR142 and 
BZRAP1-AS1, and exhibited with no proxy variants in high LD in coding regions. We thus 
focused our further investigations on the 17q22 locus (figure 1). Evaluation of the LD pattern 
in 17q22 revealed four SNPs in LD with an R2 > 0.7. Of these, rs2632516 and rs2526377, in 
very high LD (R2 =1.0), are annotated to MIR142 and, on the reverse DNA strand, located in 
Table 1. Top variants in 15 non-coding rnas significantly associated with alzheimer’s  disease 
SnP ID ncrna ID annotated gene Chr:position locus a1>a2 Maf Beta p-value
rs7384878 miR-6840 PMS2P1 7:100334426 1 C>T 0.32 -0.018 3.98×10-15
rs611418 miR-6503 MS4A4E 11:60243540 2 C>T 0.35 -0.016 2.46×10-13
rs10792264 lnc-MS4A4A-1 NA 11:60318017 2 A>C 0.36 0.012 2.29×10-8
rs636355 lnc-CCDC83-1 PICALM 11:86013618 3 T>A 0.44 -0.019 1.25×10-17
rs77162419 lnc-SLTM-2 SLTM 15:58926990 4 C>A 0.07 -0.021 8.06×10-7
rs850520 lnc-ABI3-2:5 FLJ40194 17:49255705 5 A>G 0.46 0.010 9.25×10-7
rs56229705 lnc-USP6-1 LOC101928000 17:5111494 5 G>A 0.12 0.018 1.09×10-7
rs75511804 lnc-USP6-2 LOC100130950 17:5235009 5 C>T 0.12 0.020 1.68×10-9
rs2632516 lnc-BZRAP1-1 TSPOAP1-AS1/
MIR142
17:58331728 6 G>A 0.47 -0.010 9.66×10-7
rs2526377 miR-142 TSPOAP1-AS1/
MIR142
17:58332680 6 A>G 0.46 -0.011 9.13×10-7
rs203709 miR-4531 LOC107985305 19:44658298 7 T>A 0.49 -0.020 4.15×10-17
rs12459810 lnc-ZNF180-2 BCL3 19:44746404 7 C>T 0.27 0.083 4.08×10-44
rs2965169 miR-8085 BLC3 19:44747899 7 A>C 0.47 -0.034 3.13×10-57
rs3760628 lnc-ZNF296-1 CLPTM1 19:44953968 7 G>A 0.46 0.012 9.31×10-10
rs1114831 lnc-NKPD1-1 PPP1R37 19:45133061 7 C>A 0.10 0.044 9.04×10-37
Shown are the top variants in 5 miRNAs and 10 lncRNAs (located in 7 distinct loci), exceeding the significance 
threshold (p-value < 1.02×10-6) to be associated with AD. The associations are based on the data from meta-
analysis of phase 1 and 2 of the recent AD GWAS.7 The table is sorted based on Chr and position (GRCh38.p12). 
Annotated gene, reported in dbSNP database; Chr, Chromosome; A1, Reference allele; A2, Alternative allele; 
MAF, Minor allele frequency; Beta, Effect estimate.
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the last intron of BZRAP1-AS1. The other two SNPs, rs2526378 and rs2526380, are located in 
the first and last introns of BZRAP1, a coding gene ~3kb away from the top-associated SNP 
rs2526377(figure 2). Regulome DB and HaploReg showed that three of the SNPs (rs2526378, 
rs2526380 and rs2632516) are intronic and without any predicted functions. Conversely, the 
top SNP rs2526377 is located in a highly conserved promoter region upstream of miR-142, 
which could control the expression of miR-14239 (figure 2). Using the UCSC genome browser 
and ENCODE data, we further found that rs2526377 overlaps with the well-conserved bind-
ing sites of multiple transcription factors (Supp.Table S2 and Supp.figure S2), which their 
bindings to the miR-142 promoter might be perturbed by the SNP. Moreover, the eQTL data 
from the BBMRI-NL consortium showed that the rs2632577 minor allele is associated with 
lower miR-142 expression levels in blood (p-value = 4.84× 10-11 , Z-score = -6.58).
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
figure 1. In silico and in vitro studies to elucidate the role of SnPs in 17q22 and mir-142 in aD. The 
figure summarizes our analyses to test the functionality of non-coding RNA variants at the 17q22 locus as-
sociated with AD and the role of miR-142 in AD pathogenesis. GWAS, Genome-wide association study; SNP, 
Single-nucleotide polymorphism; KO, Knock-out (miR-142-/-); NPCs, human iPS-derived neural progenitor 
cells; eQTL, expression quantitative trait loci; AD-related traits, Look-up in GWAS of cognitive ability and 
educational attainment.
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figure 2. fine-mapping of SnPs in the 17q22 locus associated with aD. a) The regional association plot 
shows the association of rs2526377 and its proxies at the 17q22 locus with AD based on the meta-analysis 
of phase 1 and 2 of the Jansen et al. paper. The p-values of variants are plotted (as −log10 of the p-value) 
against their physical position on the locus. A purple diamond represents the p-value for the top associated 
SNP rs2526377. Estimated recombination rates from the 1000 Genomes project (European population) show 
the local LD structure. The variant’s colors indicate LD with the top SNP according to a scale from r2= 0 to r2= 
1 based on pairwise r2 values from the 1000 Genomes project. B) The figure displays the localization of the four 
SNPs in strong LD (r2 > 0.7) at the 17q22 locus. These include two SNPs (rs2632516 and rs2526377) upstream 
of MIR142, and in the last intron of BZRAP1-AS1, and two SNPs (rs2526378 and rs2526380) in the first and last 
introns of BZRAP1 gene. C) The functional mapping of the locus and gene annotations from the UCSC genome 
browser are also shown below.
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As an additional analysis, we tested whether rs2526377 is connected to cognitive function-
ing prior to the clinical manifestations of AD, so that the variant can be used as early marker 
of disease. To this end, we examined the association of rs2526377 with cognitive ability and 
educational attainment using the publicly available GWAS data40,41. The SNP minor allele 
(G) was positively associated with cognitive function (P-value = 0.046, Beta = 0.011) and 
educational attainment (P-value = 0.005, Beta = 0.01), which is consistent with the protective 
effect of the G allele for AD risk.
Together, these data indicate that rs2526377 fulfilled predefined criteria for being a func-
tional variant in the 17q22 locus, which possibly function by altering the expression of miR-
142. We performed various in vitro and in silico studies to functionally show the impact of 
rs2526377 on the expression levels of miR-142 and gain insight into the function of miR-142 
and its targets in the pathogenesis of AD.
The impact of rs2526377 on the promoter activity of mir-142
The promoter region and transcription start site (TSS) of miR-142 have previously been 
characterized39, indicating that transcription of MIR142 is initiated 1205bp upstream of the 
pre-miR-142 sequence and the promoter region is located between 1305 and 1570bp upstream 
of miR-142 (figure 3a). Rs2526377 resides 1362bp upstream of the pre-miR-142 sequence 
and therefore within the miRNA promoter. To demonstrate whether rs2526377 alters the 
promoter activity of miR-142, we performed luciferase reporter assays in HEK293 cells. We 
generated reporter constructs containing either alleles of the SNP rs2526377 and transfected 
cells with the reporter plasmids, so that the effect of each allele on the promoter activity was 
evaluated. The construct carrying the rs2526377 major (A) allele exhibited 20% higher basal 
activity than the construct carrying minor (G) allele (P-value = 0.037) (figure 3b). These 
data are consistent with the eQTL data from the BBMRI-NL consortium that show rs2526377 
minor allele carriers have lower miR-142 expression levels in blood.
Potential mir-142 target genes implicated in aD
A miRNA and its target genes should be expressed in the target tissue for any biological func-
tion to be exerted. Thus, we first measured the expression of miR-142 in human brain. Both 
strands of miR-142 were expressed in the brain, miR-142-3p with an average Ct-value of 26 
and miR-142-5p with an average Ct-value of 30, relative to the endogenous control RNU6B 
with an average Ct-value of 21.5 (Supp.Table S3). To identify target genes that could mediate 
the function of miR-142 in the brain, we compiled a list of all putative target genes of miR-142-
3p and -5p from three miRNA target prediction databases (TargetsScan, miRDB and DIANA-
microT). This resulted in 885 putative target genes for miR-142-3p and 1,541 putative target 
genes for miR-142-5p (figure 4). We filtered these target genes on the basis of human brain 
expression, using the Illumina’s Human Body Map RNA-Seq dataset. We focused our analysis 
on the 814 brain-expressed putative target genes of miR-142-3p and 1,393 of miR-142-5p. To 
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examine the regulatory effect of miR-142-3p and -5p on the expression levels of their putative 
target genes, we used human iPSC-derived neural progenitor cells (NPCs). We overexpressed 
either miR-142-3p or -5p in NPCs using mirVana™ miRNA Mimics and performed differen-
tial expression analysis by RNA-Seq. To elucidate miR-142 target genes implicated in the AD 
pathogenesis, we applied the two most commonly used methods for detecting miRNA targets.
First, we conducted a hypothesis-free differential expression analysis considering all brain-
expressed target genes of miR-142. We sought to identify target genes that were significantly 
down-regulated after overexpression of the mature miRNA (3p or 5p) with FDR-adjusted 
P-value < 0.05 and fold change ≥ 1.2. Of the 814 brain-expressed putative target genes of 
miR-142-3p, 280 genes were significantly down-regulated by the miR-142-3p mimic vs 
untreated, and 74 genes were significantly down-regulated in NPCs transfected with miR-
142-3p mimic vs negative control (Supp.Table S4 and Table 2). We performed KEGG pathway 
analysis for the 74 identified target genes of miR-142-3p and observed significant enrichment 
in Regulation of actin cytoskeleton (WASL, ITGB8, APC, GNG12, CFL2, GNG12 and ENAH), 
Adherence junction (TGFBR1, WASL, RAC1 and YES1) and Axon guidance (CFL2, RAC1 and 
SEMA3D) (Supp.Table S5 and Supp.figure S3). Of the 1,393 brain-expressed putative target 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
figure 3. The genomic location of rs2526377 and its effect on the promoter activity and expression of 
mir-142. a) A schematic showing the position of rs2526377 upstream of pre-miR-142 sequence. The position 
of the miR-142 promoter region, transcription start site (TSS) and regulatory elements adapted from Skarn 
et al., PLosOne 2013.39 B) Luciferase reporter assay was performed to determine the effect of rs2526377 on 
the miR-142 promoter activity. The reporter gene constructs containing either the SNP alleles were gener-
ated and HEK293 cells were transfected with the reporter plasmids. The construct carrying the major allele 
A of rs2526377 had 20% higher basal activity in HEK293 cells than the construct carrying the minor allele G 
(P-value = 0.037). Error bars represent standard deviation (SD). *P < 0.05 compared with the control group 
(Student’s t-test). NS, non-significant.
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genes of miR-142-5p, none of them were significantly down-regulated (FDR-adjusted P-value 
< 0.05 and fold change ≥ 1.2) in NPCs transfected with miR-142-5p mimic vs negative control.
Second, we examined the association of the 814 putative target genes of miR-142-3p and 
1,393 putative target genes of miR-142-5p with AD using a candidate gene approach. To this 
end, we extracted genetic variants located in these target genes and tested their associations 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
figure 4. Identification of potential target genes of mir-142 in the brain implicated in aD. We compiled 
a list of all putative targets of miR-142-3p and -5p from three widely used miRNA target prediction data-
bases (miRDb, TargetScan, and DIANA-micro T). The target genes found to be expressed in the human brain 
were included. We overexpressed miR-142 (3p or 5p) in human iPS-derived NPCs and performed RNA-Seq 
to examine the changes in gene expression pattern. Target genes significantly down-regulated (FDR-adjusted 
P < 0.05 and fold change ≥ 1.2) in NPCs transfected with mature miR-142 mimic (3p or 5p) vs untreated and 
negative control were retrieved. Subsequently, RNA-Seq was performed on hippocampus of miR-142 KO mice 
and their wildtype littermates to confirm miR-142-mediated regulation of the identified target genes in human 
iPS-derived NPCs.
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with AD using the GWAS data7. After Bonferroni correction for the number of tested vari-
ants in all target genes of miR-142-3p (0.05 /62,515 = 8.0×10-7), four target genes passed 
the significance threshold (Supp.Table S6). Among these, PICALM (rs867611, P-value = 
2.19×10-18) was the only target gene significantly down-regulated in NPCs transfected with 
miR-142-3p mimic compared to both untreated (P-value = 1.6×10-8, fold change = 1.2) and 
negative control (P-value = 2.7×10-2, fold change = 1.1) conditions. We additionally confirmed 
the down-regulation of PICALM in NPCs transfected with miR-142-3p mimic by qPCR, 
which demonstrated ~30% reduction of the PICALM expression compared to untreated 
NPCs. A similar analysis was performed for 1,393 target genes of miR-142-5p. One target 
gene (FAM63B) passed the significance threshold (0.05/128,444 = 3.9×10-7) (Supp.Table S6), 
however, the gene was not significantly down-regulated in NPCs transfected with miR-142-5p 
mimic compared to negative controls.
Table 2. The top 20 target genes of mir-142-3p significantly down-regulated in human iPS-derived nPCs
 
Gene name
mir-142-3p mimic vs untreated mir-142-3p mimic vs negative control
fold change fDr-adj p-value fold change fDr-adj p-value
WASL 1.7 7.14×10-21 1.6 2.83×10-16
YES1 1.6 3.60×10-21 1.4 4.64×10-11
BOD1 1.6 4.78×10-26 1.4 4.64×10-11
VAMP3 1.6 2.17×10-22 1.4 9.39×10-11
IL6ST 1.6 2.33×10-22 1.4 1.03×10-10
CFL2 1.5 1.69×10-11 1.5 1.02×10-09
SUCO 1.4 7.46×10-15 1.4 4.24×10-09
CASK 1.2 3.05×10-06 1.3 8.12×10-09
TWF1 2.0 5.20×10-30 1.5 1.08×10-08
TNFRSF12A 1.2 2.58×10-01 2.0 1.12×10-08
CLIC4 1.6 3.06×10-22 1.3 1.13×10-08
TGFBR1 1.4 1.43×10-11 1.3 1.56×10-07
ITGB8 1.6 3.17×10-16 1.4 6.53×10-07
MANBAL 1.3 3.44×10-05 1.4 6.53×10-07
FAM127B 1.3 7.88×10-05 1.4 1.51×10-06
RHOBTB3 1.8 7.20×10-33 1.3 1.67×10-06
HEATR5A 1.2 16.0×10-02 1.3 1.74×10-05
RAB2A 1.3 9.41×10-09 1.3 2.00×10-05
HSPA1B 1.8 2.69×10-20 1.4 3.48×10-05
DIRC2 1.2 1.01×10-02 1.4 3.74×10-05
The table shows the 20 most significantly down-regulated target genes in miR-142-3p overexpressing iPSC-
derived neural progenitor cells (NPCs). Out of 814 predicted target genes of miR-142-3p, 280 were down-
regulated in NPCs transfected with miR-142-3p mimic vs untreated and 74 were down-regulated in NPCs 
transfected with miR-142-3p mimic vs negative control (FDR-adjusted p-value < 0.05 and Fold change ≥ 1.2). 
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validation of the identified mir-142-3p target genes in the hippocampus of mir-
142-/- mice
To confirm regulation of the 74 identified target genes of miR-142-3p in the brain, we per-
formed RNA-Seq of the hippocampus from miR-142 homozygous KO mice (miR-142-/-) and 
compared it with heterozygous KO (miR-142+/-) and wild-type (Wt) littermates (Supp.Table 
S7). Twelve (n=12) of the 74 identified target genes of miR-142-3p were up-regulated in the 
hippocampus of both homozygous and heterozygous KO mice vs Wt littermates (P-value < 
0.05) (Table 3). IPA (Ingenuity Pathway Analysis) revealed that five of the twelve target genes 
(TGFBR1, CFL2, SEMA3D, ALCAM and RHOQ) are over-represented in Nervous System 
Development and Function (P-value = 4.98×10-2-5.54×10-4) (Supp.Table S8). Among the 
twelve target genes, miR-142-3p-mediated regulation of TGFBR1 and CFL2 have also been 
validated experimentally in the previous studies.42,43
Moreover, PICALM, the target gene found to be significantly associated with AD in the 
GWAS data, was up-regulated in the hippocampus of miR-142 KO mice vs Wt littermates 
(P-value =1.5×10-2, fold change = 1.13) and heterozygous KO mice vs Wt littermates (P-value 
= 7.2×10-4, fold change = 1.2) (figure 5).
Table 3. Twelve target genes of mir-142-3p up-regulated in the hippocampus of mir-142 ko mice
Gene name
Homozygous ko vs wT Hetrozygous vs wT 
fold change p-value fold change p-value
Tgfbr1 1.22 2.43×10-03 1.20 6.68×10-03
Rhoq 1.18 3.46×10-03 1.15 1.50×10-02
Slc39a10 1.15 5.62×10-03 1.15 6.56×10-03
Ppp1r2 1.67 5.69×10-03 1.20 1.04×10-03
Cfl2 1.18 7.43×10-03 1.15 2.04×10-02
Pafah1b2 1.11 7.51×10-03 1.12 4.49×10-03
Rab1a 1.10 8.11×10-03 1.12 1.30×10-03
Rab18 1.15 1.49×10-02 1.20 2.25×10-03
Alcam 1.13 1.64×10-02 1.09 1.64×10-02
Hspa4l 1.13 2.33×10-02 1.14 1.81×10-02
Rab2a 1.12 2.55×10-02 1.13 1.70×10-02
Sema3d 1.17 2.79×10-02 1.09 2.42×10-01
The table shows 12 target genes of miR-142-3p that are up-regulated in the hippocampus of KO mice (miR142-/-). 
Out of the 74 identified target genes of miR-142-3p, which were significantly down-regulated in iPS-derived 
NPCs, twelve were confirmed to be up-regulated in the hippocampus of KO mice (miR-142-/-) compared to 
their WT (miR-142+/+) littermates (P < 0.05). 
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DISCuSSIon
Despite increasing interest in the biology of non-coding RNAs, relatively few genome-wide 
studies have thus far demonstrated associations with human disease. In this study, we per-
formed a genome-wide scan to systematically investigate the association of miRNAs and 
lncRNAs with AD by leveraging publicly available GWAS summary statistics7. We found 
seven distinct ncRNA loci significantly associated with AD including a newly identified sus-
ceptibility locus on 17q22, in which the ncRNA variant leads the signal and fulfills predefined 
criteria for being functional. The locus has not been reported as significant in the original 
GWAS, because the p-value of the top SNP in the meta-analysis of phase 1 (AD case/control) 
and phase 2 (AD-by-proxy) was above the GWAS threshold7. However, the SNP exceeds the 
GWAS threshold in the phase 1 of this GWAS meta-analysis (P-value = 1.42×10-9), combining 
data from the two large-scale AD case/control consortia, IGAP and PGC-ALZ. In the phase 
2, using the AD-by-proxy phenotype from the UK biobank cohort, the association between 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
figure 5. The interaction and regulatory effect between mir-142-3p and its three target genes. The fig-
ure illustrates the binding of miR-142-3p to its three highlighted target genes (TGFBR1, CLF2, and PICALM). 
The expression of these target genes were significantly down-regulated in human iPS-NPCs transfected with 
miR-142-3p mimic vs untreated, and in iPS-NPCs transfected with miR-142-3p mimic vs negative control. In 
contrast, the expression of these target genes were up-regulated in the hippocampus of miR-142 KO mice vs Wt 
littermates. Error bars represent standard deviation (SD). *P < 0.05, **P < 0.01 and ***P < 0.001 compared with 
the control group (Wald-test).
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rs2632516 and AD is less significant (P-value = 5.0×10-3), but still in the same direction. The 
lower association signal for the 17q22 locus in the UK biobank cohort could be explained by 
differences in case ascertainment of AD. In the UK biobank, Alzheimer dementia is ascer-
tained via self-report information from family history (parent or first-degree relative with 
AD or dementia) as a proxy-phenotype for the participants44. This method relies on people to 
provide accurate information about whether their parents developed AD, for which misclas-
sification of case status is of greater concern than consortia relying upon clinician reported 
diagnoses. In addition, a trans-ethnic GWAS, by adding more samples to the IGAP GWAS 
data, recently reported the significant association of 17q22 with AD45. In this trans-ethnic 
GWAS, however, the leading ncRNA variant in the 17q22 locus was annotated to the closest 
protein-coding gene (BZRAP1), and the potential impact of miR-142 has been overlooked. In 
contrast a more recent GWAS, investigating the association of rare coding variants with AD, 
with an even larger sample size did not find any significant association between rare variants 
in BZRAP1 gene and AD46. In this line, our results demonstrated that miR-142 is the most 
likely functional target in the 17q22 locus implicated in AD pathogenesis.
Genetic variants in miRNA-encoding sequences have been shown previously to affect 
miRNAs expression and subsequently influence gene regulation in complex diseases47-49. 
Moreover, the functional impact of variants on the promoter activity of miRNAs has been 
revealed, most notably for rs57095329 located in miR-146a, by altering the miRNA processing 
and expression level50. Here, we demonstrated that rs2526377 affects the promoter activity and 
reduces the expression levels of miR-142. Previously, Skarn et al. characterized the miR-142 
promoter region and demonstrated that DNA methylation of specific CpG sites in the region 
represses the promoter activity and reduces the expression level of miR-142 in mesenchymal 
stem cells39. Moreover, an independent study by Mor et al. revealed that hypomethylation 
of the CpGs in the miR-142 promoter region increases the miRNA expression level in the 
prefrontal cortex of autism patients51. These data may indicate that rs2526377 attenuates the 
risk of AD via reducing the miR-142 expression levels in the brain.
MiR-142 is a highly conserved miRNA amongst multiple invertebrate and vertebrate spe-
cies. The role of miR-142 has extensively been studied in the hematopoietic system, lung de-
velopment and cardiac hypertrophy52. Convergent evidence from multiple investigations also 
indicates the expression of miR-142 in the brain, suggesting that dysregulation or malfunction 
of miR-142 contribute to the pathogenesis of brain disorders. For instance, Junker et al. re-
ported miR-142 among the 10 miRNAs that are more abundant in active multiple sclerosis 
(MS) brain lesions than normal white matter, and suggested miR-142 to be involved in the 
brain inflammatory and degenerative diseases53. Similarly, Mandolesi et al. observed that miR-
142 is increased in the CSF of patients with active MS54. Moreover, Sorensen et al. performed 
miRNA expression profiles in CSF and blood of patients with AD and found a number of 
differentially expressed miRNAs, in which miR-142 is one of the significantly up-regulated 
miRNAs in AD patients compared to controls55. Two independent studies also revealed that 
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the expression of miR-142 is increased by age56,57. Here, our expression data confirmed that 
both mature miR-142-3p and -5p are expressed at relatively high levels in the brain; though, 
our RNA-Seq analysis proposed miR-142-3p, which is the guide strand of miR-142, to be 
more active on the regulation of its target genes in the brain. Consistent with this notion, 
Lau et al. have performed miRNA expression profiling of the hippocampus of a cohort of 41 
AD patients and 23 age-matched controls and found miR-142-3p among the 15 significantly 
up-regulated miRNAs in the AD group58. Moreover, miR-142-3p has been reported as one of 
the eight miRNAs up-regulated in synaptoneurosomes from forebrains and hippocampus of 
mice during prion disease59. Together, these data endorse that alterations in the expression 
of miR-142 in the brain could confer AD risk, where higher levels of miR-142-3p increase a 
person’s risk of developing Alzheimer’s.
Up-regulation of miR-142 in the brain may influence AD risk through different mechanisms. 
Gene ontology analysis on the putative target genes of miR-142-3p and -5p has shown enrich-
ment in categories related to synaptic transmission (dopaminergic synapse, neurotrophin 
signaling, axon guidance) and signal transduction (TGF-β signaling, MAPK signaling, ErbB 
signaling)51,60. Mandolesi et al. proposed miR-142 to be related to neuro-inflammatory changes 
in the brain occurring during MS by regulating the expression of IL-1β54. Further, Chaudhuri 
et al. suggested the involvement of miR-142 in autoimmune and neuro-inflammation in the 
brain, via miR-142-mediated repression of SIRT1 in primary human neurons61. In an inde-
pendent study, Chaudhuri et al. verified that miR-142 indirectly reduces MAOA protein level 
via regulating SIRT1 expression62. Since MAOA is a neurotransmitter-metabolizing enzyme 
and delaminates serotonin, melanin, epinephrine and norepinephrine, they postulated that 
miR-142 up-regulation might contribute to change the dopaminergic neurotransmission by 
lowering MAOA expression and activity. In this study, we further demonstrated miR-142-3p-
mediated regulation of multiple target genes in the brain that are involved in the pathways 
underlying AD. TGFBR1 and PICALM, among others, are of particular interest (figure 6). 
TGFBR1 has been shown in several studies to be implicated in AD pathogenesis63-68. The 
regulation of TGFBR1 expression by miR-142-3p has been experimentally confirmed at 
mRNA and protein levels in previous studies43,69. Our differential expression analysis for all 
miR-142-3p target genes demonstrated that TGFBR1 was significantly down-regulated in 
miR-142-3p overexpressing human iPS-derived NPCs and the top target gene up-regulated 
in the hippocampus of miR-142 KO mice. Locating at the intersection of anti-inflammatory, 
anti-aging and neuroprotective pathways, TGFBR1 makes a promising molecule for mediat-
ing the function of miR-142-3p in AD.
PICALM is ubiquitously expressed in all tissue types with prominent expression in neurons 
and is non-selectively distributed in pre- and postsynaptic terminals, where it plays an es-
sential role in the fusion of synaptic vesicles to the presynaptic membrane in neurotransmitter 
release70. Several GWA studies have independently confirmed the association of PICALM 
with AD8,46,71. Recent studies have also shown that PICALM level is reduced in the AD brain 
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endothelium and postulated that it can potentially lead to Aβ accumulation in the brain by 
hindering LRP1-mediated Aβ transport72,73. These data strongly suggest that derepression of 
PICALM in response to the reduced miR-142 expression may decrease AD risk that deserve 
further and more deep investigation in future experimental work.
Conclusions
In this study, we endorse 17q22 as a susceptibility locus for AD and provide evidence demon-
strating that miR-142 is the most likely functional target in the locus involved in AD patho-
genesis. Furthermore, we revealed miR-142-3p-mediated regulation of multiple target genes 
in the brain that are implicated in the inflammatory and neurodegenerative manifestations of 
AD. These include two well-validated AD-associated genes, TGFBR1 and PICALM, of which 
their derepression in the brain due to reduced expression levels of miR-142-3p may decrease 
risk of AD. Our findings may also suggest the therapeutic potential of miR-142 inhibition for 
AD, which warrants further investigations in future.
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figure 6. rs2526377 in the promoter of mir-142 modulating its expression and conferring risk of aD. The 
SNP rs2526377 occurring within the promoter region of miR-142 alters the promoter activity and reduces the 
expression level of miR-142. Downregulation of miR-142-3p in the brain results in derepression of multiple 
target genes (e.g., TGFBR1 and PICALM) that contribute to the pathogenesis of AD.
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Murine Stem Cell Virus-Bar Coded; TSS, Transcription start site; PCR, Polymerase change 
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False discovery rate; Wt, wild-type; KO, Knock-out.
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This thesis set out to test the functionality of human iPS technology for human brain disease 
modeling. In the preceding chapters I reported on several studies where we successfully used 
iPS technology to answer questions on human molecular and cellular neurobiological func-
tioning. We established a simplified protocol for obtaining mature neuronal networks and 
revealed on transcriptional regulation of human BDNF and sublocalization of human UBE3A. 
We reported that the reprogramming procedure leads to silencing of the FMR1 gene even in a 
healthy individual without concomitant methylation of the full mutation. Lastly, we identified 
a functional variant associated with lower risk for AD.
Nonetheless, since the emergence of iPS technology several features of its use have come to 
light that require proper attention. The largest and most disturbing discovery is that not all 
pluripotent stem cells are equal in their capacity to differentiate into desired cell types in vitro. 
Numerous studies now point towards variation at the genetic and epigenetic level between 
clones that result in functional variability between cell lines and heterogeneity between clones. 
Below I discuss the sources of this variability and how we have combatted these in our studies.
Donor Cell-InDuCeD GeneTIC varIaBIlITy
The first introduction of genetic variability arises with the choice of donor cell from which 
an iPS line is generated. Nowadays, many different cell types have proven suitable as donor 
cell. In the initial publication on reprogramming by Takahashi et al. dermal fibroblasts and 
fibroblast-like synoviocytes were used1. Ever since other groups confirmed that also blood 
erythroblasts, hair keratinonocytes2,3, cells from tubular networks from the ureters, bladder 
and urethra disposed in urine4,5, and dental pulp cells6 are converted to iPS by the Yamanaka 
factors Oct4, Sox2, Klf4, c-Myc. Also cells derived from lesser accessible tissues proved suf-
ficient such as neural stem cells, hematopoietic stem cells and liver cells7. Although all of these 
cells are originally formed from different germ layers and their conversion towards a pluripo-
tent state is possible, increasing reports document that the efficiency differs as a function of 
the donor cell source7,8. This may depend on endogenous expression of the Yamanaka factors 
themselves9. Regardless, there seem to be no limitations depending on sex, ethnic group, 
disease condition, or interestingly age. This latter point however may require extra attention. 
As individuals age, their DNA accumulates mutations either induced by the environment or 
because of mistakes in the DNA proofreading process during cell division10,11. These somatic 
mutations not necessarily turn into harmful tissue for the individual, yet this phenomenon 
in iPS-based studies may pose a problem: the starting donor cell culture may be genetically 
heterogeneous. Several groups indeed confirm this12–14. Albeit a small population of cells, 
there are unique mutations not present in the culture as whole. Next to inherent heterogeneity 
of the used tissue, a mutational load for cell divisions (approximately 0.02 per cell division12) 
also applies. While the contribution of variability to the culture is small, the subsequent step 
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in iPS line generation requires reprogramming and colony picking. Here individual cells form 
individual colonies and initial neglectable variety runs the risks of being established within 
a cell line. Interestingly also, several studies suggest that somatic mosaicism, the presence of 
multiple cell clones with different genotypes in the same individual, is common in normal 
development15,16. This poses a dilemma on modeling. What is the reference genome or are the 
reference genomes? What is the contribution of each? Are somatic mutation facilitating the 
phenotype in an individual or are they non-functional?
In our studies we have tried to deal with donor cell variability is several ways. Firstly, our 
iPS lines were derived from skin fibroblasts, where our oldest donor was 57 years old and our 
youngest donor 3 years old. We made use of skin fibroblasts because of their large source and 
ease for culturing. This would keep the culture-induced mutation rate as low as possible.
Ideally, we would use younger cells, such as hematopoetic stem cells which are rare in pe-
ripheral blood, but rich in bone marrow, umbilical cord blood and placenta17. Moreover, these 
last two have multi-lineage differentiation potential and a low mutational load. However in 
practice this may pose a problem. Such cells are not commonly stored. Since a large group of 
psychiatric disorders and degenerative disorders present themselves only decades after birth, 
a large source of donor cells may be the next best option in line for modeling them with iPS. 
Next to fibroblasts, another convenient source of cells are urine-derive donor cells4,5. Also no 
medical assistance is necessary to obtain them. However little is known about this derived 
source. Peripheral blood also represents itself as a rich source, yet it contains erasable im-
munogenic marks, and may contain infections7,8. Overall, conscious decisions should be made 
with respect to donor cell type, and quality control checks for spotting heterogeneity in donor 
cell population may be of help.
reProGraMMInG-InDuCeD GeneTIC varIaBIlITy
Apart from variability induced by the donor cell population, several groups have reported on 
additional mutations and genomic alterations after reprogramming. Gore et al. indicated that 
in 22 tested iPS line an average of 6 exomic mutations per line was gained. It is unclear though 
at which passage number the lines were tested. Interestingly, Ji et al. indicate an average of 12 
mutations per iPS cell line at passage 613. Their study focused on the derivation of 5 individual 
iPS lines from one fibroblast source. Additionally, large chromosomal aberrations were also 
found in derived iPS lines. Several groups report on abnormal chromosomal aneuploidy 
(multiple copies of the same chromosome), chromosomal trisomies14,18, copy-number variants 
(CNV)18,19, and deletions and duplications18,20. Taapken et al.21 reported that of 552 cultures of 
219 iPS lines, 12,5% of the cultures have an abnormal karyotype. This indicates that significant 
genomic aberrations emerge during reprogramming, colony picking, and expansion.
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The genes affected by these mutations were not random. Many of the mutations were found 
in genes related to cancer12, and culturing specifically selected for them12. These mutations 
may give the cells a growth advantage. CNVs were also found in genes with established roles 
in cancer18. Most chromosomal aberration were detected on chromosome 12 and 17 which 
carry genes benefitting embryonic tumors and stem cell adaptation14. Similarly, Hussein et al. 
ascertained that compared to 6596 common CNVs found in 270 healthy individuals, 37% of 
the found CNVs were novel but enriched in maintaining an undifferentiated state, or associ-
ated with human ES differentiation and maintenance19. They also indicated that deletions were 
commonly found in common fragile sites in the genome and subtelomeric regions. Although 
others could not confirm that18. On a karyotype level trisomy 12 was the predominant abnor-
mality in 31,9% of the hundreds of iPS lines tested. However 42% of the located chromosomal 
abnormalities were nonrecurrent between lines.
Testing for mutations in the gene however only represents the genomic status in that mo-
ment, as mutations seem to be acquired and lost with passaging. In a small study Ji et al. 
indicated that at passage 12, 2 of the 5 tested iPS lines had lost 2, and 1 point mutations, 
and two iPS lines had gained 1, and 3 point mutations13. In another study an increase of 4 
mutations from passage 9 to passage 40 was found12. A rough estimation therefore is approxi-
mately 1 mutation per 10 passages. However both studies examined mutational burden in the 
exome. Additional mutations may have been incorporated in the non-coding genome as well. 
Apart from the exome, the DNA also holds regulatory sequences, the proper functioning of 
which ensures adequate transcriptional regulation of the cell22,23. Therefore, the amount and 
effect of acquired mutations may in fact be higher. Long-term culture also increases genomic 
abnormalities, where aneuploidy is rare in low passage iPS, but increase at later passages24. For 
example in one iPS line (hiPSC 18)25,26 Marshay et al. measured a normal karyotype at passage 
45, passage 58 presented a mosaic cell line with normal cells and trisomic cells containing 
three copies of chromosome 12. However at passage 63 the line had acquired a full trisomy of 
chromosome 12. Deletions were mostly found in early passages (passage 5-8), and duplica-
tions in later passages (passage 25-34)20. Some early deletions actually receded, indicating 
that they are positively selected for during reprogramming, but negatively selected for during 
passaging. With regard to CNVs Hussein et al. found that they were negatively correlated 
with passage numbers19. This indicated that with passaging CNVs were selected against, and 
their number and length decreased over passaging time. Over time, therefore, cultures were 
mosaic. Others however did not find an association between CNVs and passage number18.
To ensure that our iPS lines did not carry genetic abnormalities we checked their karyotype 
between p5-p10 after colony picking and every 10 passages. We kept our lines in culture for 
the least amount of time necessary. Lines with aberrant karyotypes were not used for sub-
sequent studies. Yet we did not perform exome or whole-genome sequencing at any of the 
passages. A major challenge we encountered was that individual clones are selected not only 
in the reprogramming procedure, but also in iPS maintenance. Culture of any given line in 
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routine-practice therefore is highly branched. A way to combat this disadvantage is to work 
with highly efficient reprogramming strategies, and iPS maintenance protocols that are robust 
and standardized such that colony picking is prevented as much as possible. Next to this, an 
administrative system to keep close track of genetically surveyed lines, and their pedigree 
relationship between cryopreserved stocks, live cultures and cells from which data is derived 
may greatly benefit detecting any genetic abnormalities that may obscure experimental data.
reProGraMInG-InDuCeD ePIGeneTIC varIaBIlITy
Next to genetic variability, also epigenetic variability occurs in cell culture. In essence cel-
lular reprogramming as is done by the Yamanaka factors, results in the repression of genes 
responsible for differentiation and activation of genes responsible for reprogramming. Here 
epigenetic marks are responsible for the gene-specific expression.
Different types of epigenetic marks exist. They are divided in two major classes27: DNA 
methylation and histone modifications. DNA methylation is a biochemical process where a 
methyl group (CH3) is covalently bound to the cytosine in the DNA. Through this modi-
fication access to the DNA is hampered. Also methyl-CG-binding domain proteins can be 
recruited. They remodel histones and form compact, inactive chromatin so-called heterochro-
matin. Regularly high repeats of CG’s are found near gene promoters and transcriptional start 
sites. These are called CG-islands. These islands are targets for methylation. Methylation of 
CG-islands generally leads to inhibition of transcriptional activity of genes in their vicinity, 
whereas unmethylated CG-islands allow activation.
For most genetic locations DNA methylation is identical on both alleles. However, at 
imprinted genes and X-chromosomes though, only a single allele is methylated normally. 
This results in silencing and parental-specific expression of this gene. At this point about 
60 human genes are known to be imprinted28. There are imprints that are established in the 
germline, whereas others are derived in somatic cells during early embryonic development. 
Imprinting defects are amongst others associated with neurodevelopmental diseases such as 
Silver-Russell, Beckwith-Wiedermann, Prader-Willi syndromes and Angelman Syndrome29.
The second class of epigenetic marks is histone modification. Histones are proteins around 
which the DNA winds itself. Wound up DNA together with the histone is called a nucleo-
some. Histones can also undergo covalent modifications such as acetylation, phosphorylation, 
methylation, SUMOylation, and ubiquitination30. 
A another class of epigenetic-related processes is covered by regulation through noncoding 
RNA expression27. It has become evident that noncoding RNAs are involved in controlling 
several epigenomic phenomena. One example is the dosage compensation mechanism of the 
X-chromosome through the long non-coding RNA, XIST (X-inactive specific transcript).
This mechanism ensures X-chromosome inactivation (XCI). However noncoding RNAs are
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also involved with silencing genes and repetitive DNA sequences by post-transcriptional and 
transcriptional RNA interference-related pathways through microRNAs and siRNAs.
Cellular reprogramming requires the substitution of the donor cell epigenetic marks, which 
normally are stably inherited through subsequent divisions, with that of the epigenetic marks 
specific to iPS cells29. Subsequent modeling of human brain cells then obliges remodeling 
of the iPS epigenetic landscape to that of the desired brain cell. This however turns out not 
to be straightforward. In the original study by Takahashi et al. iPS were promoted for their 
comparison to ES cells with respect to morphology, proliferation, gene expression and differ-
entiation potential1. However, at the epigenetic level iPS and ES cells share some differences. 
For example, when DNA methylation patterns in iPS cells are compared to those in ES cells, 
differentially methylated regions (DMR) in genes are detected31–34. Similarly, at several genes 
methylation patterns are found in iPS that are specific to the donor cell, but are not found in 
ES cells. This epigenetic memory phenomenon can either be labeled as aberrant or incomplete 
reprogramming, or as an iPS-specific epigenetic signature. Lister et al. indicated that 51-56% 
of 3507 DMRs in CG islands found between iPS on the one hand and donor cells or ES cells 
on the other hand, were specific to the iPS cells only. Sixty-nine percent of these DMRs were 
present in at least two iPS lines, and 16% of the DMRs were found in 5 iPS lines. These may 
represent iPS-specific epigenetic signatures. These iPS-specific signature marks were spread 
over the genome so they did not specifically disrupt certain processes. In these 5 lines 92% 
of the DMRs turned out to be hypomethylated compared to the donor cell, indicating that it 
mostly was methylation that was not properly reset.
Ohi et al. found a similar trend. They differentiated hepatocytes, newborn foreskin fibro-
blasts, and adult melanocytes to iPSs. In low passage iPS cells (below 20) they found that genes 
that were expressed at high levels in donor cells, were repressed in iPS, yet their expression 
remained higher than in ES cells. The same applied for poorly expressed genes in donor cells: 
they were more highly expressed in iPS, but not as high as in ES cells. Next to this they found 
that DMRs were not dependent on any of the donor cell type. However, they did find a non-
random pattern of incompletely silenced genes. These genes tended to be physically isolated 
from other genes that did undergo silencing. This could indicate that the silencing machinery 
or DNA methyltransferases may be inefficient or delayed at certain donor genes.
Also, when iPS were differentiated to trophoblast lineage cells, hundreds of DMRs were 
found between ES cells and ES-derived tryphoblasts31. The differences were attributed to donor 
cell DMRs, and iPS-specific DMRs. This indicated that aberrant methylation is maintained in 
differentiated lineages. Bar-Nur et al. reprogrammed pancreatic islet beta cells towards iPS, 
and found that pluripotency genes indeed were active, however donor cell genes were more 
methylated34. Also, hypomethylated genes in the islet cells were still hypomethylated in the iPS 
line, while normally methylated in lines derived from fibroblasts, or in ES cells. Next to this 29 
mega-regions of dissimilar methylation were found in genomes31. Half of them were greater 
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than 1 MB, the largest was 4.8 MB. Many of these regions were found in close proximity to 
centromeres and telomeres. 
Nazor et al. also found aberrant methylation in differentiated cell types35. They studied 
methylation in several female iPS lines, and discovered that numerous had partial or low 
methylation of X-chromosomes. This coincided with XIST expression, where a higher expres-
sion of the non-coding RNA XIST that mediates silencing, was related to higher methylation 
levels on the X-chromosome. This difference was found even though all clones were passaged 
and managed in the same way. Also, where the majority of lines in early passages showed XCI 
and XIST expression, at late passages they showed loss of XCI and XIST expression. Similar 
patterns were observed by Mekhoubad et al.36 This loss of imprinting resulted in biallelic 
expression of the X-chromosomes. When these cells were differentiated to the NPC and OPC 
lineages, these partial methylation patterns persisted. Apart from epigenetic changes that are 
established during reprogramming and passed through to differentiated lineages, epigenetic 
changes thus also occur during passaging over time.
We did not perform assays on DNA methylation patterns in our derived iPS or differenti-
ated neural cells. However we did experience the epigenetic altering effect of reprogramming 
in our studies. In chapter 5 we worked with fibroblasts from a healthy individual who carries 
a full mutation of the FMR1 gene. Where a full mutation normally induces silencing of the 
gene by DNA methylation of the FMR1 promoter and additional histone modifications, this 
individual carried unmethylated FMR1 alleles in fibroblasts and showed FMR1 expression. 
To study the effects of epigenetic silencing of FMR1 in fragile X syndrome we reprogrammed 
these fibroblasts into iPS lines. However in the iPS state, the FMR1 promoter of this healthy 
individual was methylated. This illustrates an example of the effect of reprogramming on the 
epigenome that render iPS unusable for modeling. Since in this case the epigenetic silencing 
process was our area of focus, this discrepancy in methylation status came to our attention. 
However, certain epigenetic marks may play subtle roles in disease modeling, and where the 
involved marks are even unknown, these as of yet unpredictable differential epigenetic marks 
may cause variability and faulty results.
One of the limitations of our study is that we did not evaluate the methylation pattern of the 
PWS-IC of the cells used for our UBE3A localization experiments (Chapter 4). A methylated 
PWS-IC inhibits expression of UBE3A-ATS. This long non-coding RNA silences expression 
of the UBE3A gene. The UBE3A-ATS is exclusively expressed in neurons. As such, in neurons 
derived from iPS with unmethylated PWS-ICs no UBE3A expression would be observed. 
Nonetheless, we observed UBE3A expression in NPCs derived from iPS generated from 
fibroblasts from an AS patient and in NPCs and neurons of a healthy control. Therefore we 
assume that the PWS-IC must have been methylated. However, we are not able to ascertain 
that UBE3A expression in neurons from the healthy control was not due to two active UBE3A 
alleles. Nonetheless, several studies reported on fibroblast-derived iPS lines where the PWS-
IC centers in different iPS lines was methylated37–39, confirming the use of iPS for studying 
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UBE3A expression. However a recent study found differential methylation of PWS-IC and 
subsequent aberrant expression of the closely located SNRPN gene, pointing towards the 
necessity to thoroughly check methylation status in genes under investigation40.
InHerenT GeneTIC varIaBIlITy
Several researchers have established acquired genetic and epigenetic variability not to be the 
biggest source of in vitro variation41–43. Inherent genetic variation between individuals seems 
to play a much larger part. Burrows et al. collected blood and fibroblasts for iPS reprogram-
ming from two males, and two female individuals. Deriving multiple lines from each donor 
cell source allowed them to compare cell-type of origin, epigenetic memory, and their intra- 
and inter-individual components to variability. Their gene expression and DNA methylation 
data showed that the contribution of cell type of origin to variation in gene expression and 
methylation data was very small. There was an epigenetic memory of the donor cells in the 
iPS lines, but this contributed only marginally to variation. This was also confirmed by oth-
ers43. Burrows et al. concluded that only a handful of differentially methylated sites influenced 
regulatory variation but that genetic background captured a much greater proportion of the 
variation seen in gene expression and methylation assays.
This fact was also supported by Kyttällä et al.42 who showed that only 7-25% of the DMRs 
resemble those from the donor cell. On average 70% of these DMRs are equal to those found 
in ES cells. They find that the majority of variance found in gene expression and methylation 
assays is dependent on genetic background. The genes differentially expressed between donors 
were mostly those encoding transcriptional factors related to maintenance and differentiation 
of iPS. Also, when iPS were differentiated they found that the differences in gene expression in 
iPS were reflected in the gene expression in differentiated cells types as well.
Subsequent studies were able to more concretely define genetic variability to the outcomes 
of measured in vitro variance18. In a comparative study using hundreds of lines from 301 
individuals, Kilpiken et al. calculated that 21.4-45.8% of variance measured in immuno-
cytochemical stainings, and 7.8%-22.8% of variance measured in cellular morphology is 
attributable to genetic variability between individuals. In a gene expression assay were 25.434 
probes were tested, variation of 46.4% of the probes was explained by gene variability. CNVs, 
culture conditions, passage numbers or gender explained 23.4%, 26.2%, 2%, and 1.9% of the 
variance, respectively. Carcamo-Orive et al. found that 50% of the variance found in gene ex-
pression data was explained by genetic background. They added to this that several expression 
quantitative trait loci correlated with gene expression levels. It appeared that cis-regulatory 
variants contributed more to variance than shared environment and technical processing. The 
genes that varied most were related to developmental processes such as pattern specification, 
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regionalization, and organ and embryonic morphogenesis. This indicated that developmental 
pathways contributed at length to variability between lines.
In our studies, to correct for variability between lines, we made use of three lines from three 
different individuals in Chapter 2, where we tested the robustness of our neuronal differentia-
tion protocol. For the remaining of our studies we made use of one line per condition. Despite 
the reported variability we found robust and reproducible results in our experiments. The 
reason we asked very specific questions that did not require comparison between different 
iPS lines may have been the reason for that: in Chapter 2 we were testing the robustness of 
our protocol which was confirmed by the development of neuronal cultures from three inde-
pendent lines in several rounds of differentiation. In Chapter 3 we made use of one ES line, 
and one iPS line for investigating transcriptional control of the BDNF gene. In Chapter 4 we 
compared overexpression of different UBE3A protein isoforms. In Chapter 5 we evaluated the 
epigenetic characteristics of the FMR1 promoter of several lines before and after reprogram-
ming. As such our experiments did not suffer from inherent genetic variability between lines.
Whenever phenotypes between iPS lines are to be compared, an alternative study design 
would be the use of isogenic lines: lines theoretically only differing in the genetic perturbation 
to be studied.
In general three types of iPS-based studies are discernable: the study of fundamental bi-
ology irrespective of genetic variations or mutations, the study of a monogenic disease, or 
a multigenic disease. In each study the genetic background of the stem cell line to be used 
needs to be considered carefully. Commonly donor cells from a healthy subject are used to 
generate control stem cells lines. Control cell lines are used for fundamental studies unrelated 
to genetic variations and mutations as well as in ‘patient vs control’ designs. Yet the question 
remains what healthy subjects entail. Individuals could be free of disease at the moment of 
assessment, and develop disease later in life. Collection of donor cells from aged subjects 
may not be accommodating because of mutational load in older cells10. In this case selection 
of sufficient amount of lines would mitigate line-specific effects. This makes the selection of 
youthful donor cells-derived lines a possibility, in that way eliminating high mutation load 
derived from adult somatic cells. Retrospect check-up on donors when they reach the critical 
age for disease development is an alternative as well.
In case of studying monogenic diseases with strong effect sizes it may suffice to select unre-
lated controls44–46 (such as in chapter AS) or at best healthy family members to compare with 
the patient-specific lines47. In case of smaller effect sizes variation between lines can partially 
be taken away by making use of isogenic lines, lines identical other than the mutation to 
be studied. This solution should mitigate the unintended genetic and epigenetic variability 
that remains between two unrelated stem cell lines48. Yet several points have to be taken into 
account. Commonly used procedures for gene editing entail zinc fingers, TALENs and Crispr-
Cas9 where the use of the latter nowadays becomes standard-practice in labs. Nonetheless, al-
beit they are being improved, these techniques can unintentionally create mutations elsewhere 
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in the genome in the editing procedure49. Several economical high-throughput methods are 
being developed to check the genome for additional mutation. Yet these would have to be-
come standard-practice as well in laboratories as often only in silico predicted off-targets are 
examined. Unfortunately there is accumulating evidence that the current algorithms have low 
prediction accuracy49. Taking into account the variability induced by the in vitro procedures, 
the chance on differences between derived isogenic lines in point mutations as well as aberrant 
epigenetic landscapes increases with every passage (see above).
In case of studying multigenic diseases where uncertainty remains on which genetic per-
turbation is responsible, patient and control selection is a delicate business. Some suggest 
that selecting patients and controls with clustered risk-scores may create enough power for 
phenotype detection50. Surely high numbers of lines are necessary to tease out the phenotype.
Nonetheless, where possible the use of isogenic lines seems the best way forward to reduce 
genetic and epigenetic variability.
IN VItRo DIfferenTIaTIon-InDuCeD varIaBIlITy
Another source of variability seen in human brain modeling studies is the neural differentia-
tion procedure itself. Most differentiation strategies are based on modulating naturally oc-
curring specialization in the brain. In development, neurons are derived from the ectoderm, 
one of the three germ layers generated in early embryogenesis51. Ectoderm forms the neural 
tube, which gives rise to the brain and spinal cord. These developmental steps are triggered 
by the expression of morphogens in strict patterns along the rostral-caudal axis (Fibroblast 
Growth Factors (FGFs), Wingless/Int (WNTs), retinoic acid (RA)) and ventral-dorsal (WNTs, 
Bone Morphogenetic Proteins (BMPs), Sonic Hedgehog (Shh). Under influence of FGF and 
RA ectodermal tissue develops into neuroepithelia. Subsequently, a specific combination of 
morphogens in the neural tube triggers the neural stem cells in that area to develop into either 
neuronal or glial progenitors52. These progenitors differentiate into mature neurons or astro-
cytes and oligodendrocytes, respectively. In the differentiation process similar developmental 
stages are passed. An important step is the induction of neuroectoderm. From there on, neural 
stem cells and precursors continue on to differentiate into specific neuronal subtypes with or 
without addition of specific morphogens.
There are several ways to induce neuroectoderm in vitro. One way is the isolation of neu-
roectoderm from embryoid bodies53. Embryoid bodies (EBs) are three-dimensional cellular 
aggregates of IPSCs, obtained when cells are grown in suspension. This method allows the 
spontaneous differentiation of IPSCs to cells of the three germ layers. When treated with 
specific growth factors or morphogens such as RA, the proliferation of neuroectoderm is pro-
moted. Subsequently, cells are plated in neuronal supporting media. However, the drawback 
of this system is that embryoid bodies can vary in size, which results in inconsistent yields 
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of neural progenitors. Since the inner cell layers of embryoid bodies are difficult to reach for 
morphogens, radial concentration gradients emerge which induces heterogeneous cell types.
As EBs are derived from iPS, their homogeneity also plays an important part. In vivo the 
pluripotent state is a transient one, such that in vitro critical media components are necessary 
to maintain the pluripotent state1,54–57. Yet iPS occasionally escape the pluripotent state and 
randomly differentiate, thereby reducing the line’s overall pluripotency. Whenever these cells 
are used for targeted terminal differentiation the outcome is inevitably a mixed population of 
desired and undesired cells.
Kilpinen et al. tested over hundreds of lines from 301 individuals and found that 84% of 
them are classified as pluripotent by the Pluritest, a tool for pluripotency assessment by whole 
genome expression analysis18. In an average iPS line 18-62% of the cells co-express the pluri-
potency markers NANOG, OCT4 and SOX2. Whenever an iPS line was differentiated to one 
of the germ layers 70%, 84% and 77% of the cells in the line would express markers specific 
for respectively endoderm, mesoderm, and ectoderm. This indicates that roughly one-sixth 
of the lines are pluripotent, and that roughly one-fourth of the cells do not differentiate to the 
desired germ layer.
After neural induction of EBs from iPS, EBs are commonly plated and display neural 
rosettes. Series of radial migration of NPCs occur, yet however not all these NPCs are the 
same58. They are an ensemble of several neuronal precursors such as radial glia, intermedi-
ate progenitors, symmetrically and asymmetrically dividing NPCs59, but also progenitors of 
oligodendrocytes, and astrocytes60. Depending on the question to be asked, treating them as 
one population may result in high batch-to-batch differences. Next to that, terminal neural 
differentiation highly depends on the composition of the original NPC population. As such, 
mixed NPC populations may lead to dissimilar terminally differentiated neural cultures if 
the ratios of the different types of progenitors are not the same. As terminally differentiated 
cultures derived from NPCs by dual-SMAD inhibition also go through a neural rosette stage, 
the same caution should be taken.
Apart from the cell type diversity of the NPC population, another point to take into account 
is the age of the cell. Regular passage of NPCs may contain migrated NPCs, as well as newly 
born NPCs. These cells represent different neurodevelopmental stages of NPCs: each of these 
cells may have a different temporal-spatial expression profile, such as in the brain. Practi-
cally, the first rounds of passaging of the NPC population deliver mostly neuronal precursors, 
where later populations produce more astrocytes. Whenever this tipping point occurs though 
is unknown. Yet in our studies we find this to be around 10 passages of the NPC popula-
tion. During in vivo brain development different NPC populations co-exist simultaneously; 
however, for modeling neurodevelopmental diseases the fine balance of the population may 
be crucial.
The shortest protocols to differentiate neuronal cells with basic electrophysiological proper-
ties from a common neural progenitor need 6 weeks of in vitro culturing from a neuroectoder-
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mal stage. As the protocols to generate neurons lengthen and several procedures ((sub)plat-
ing, refreshing, stable environmental factors) need to be performed, well-to-well variability is 
increased, such as differences in cell density and cellular heterogeneity. Volpato et al. tested the 
reproducibility of the Shi et al. protocol61,62. They used two lines: one control line, and one line 
containing a mutation in the PSEN1 gene, in 5 different laboratories and examined the RNA 
and protein profiles of differentiated cortical neurons. Within each laboratory the differences 
between lines were visible (three independent neuronal induction). However across multiple 
laboratories differences in expression between the two lines were not consistently detectable. 
They indicated cell type heterogeneity as the major contributor to variability. Subsequently, 
they also collected 771 individual transcriptomes of cells in the culture. Here 4-5 subpopula-
tions were identified within the neural cultures expressing neuronal, astrocytic, oligodendritic 
and microglial marker genes. They also found out that factors that hampered cross laboratory 
comparison were iPS passage number before differentiation, the number of passages before 
terminal differentiation plating, media volume changes, feeding at weekends, and use of fro-
zen progenitors. They hypothesized that the factors may alter epigenetic and cellular programs 
that determine cell fate choice, eventually influencing the composition of the final culture.
For the majority of the studies we made use of the differentiation protocol described in 
Chapter 2. In this chapter we showed reproducible outcomes of neural cell composition. In 
Chapter 4 we made use of fluorescence-activated cell sorting (FACS) to enrich our NPC popu-
lation, thereby increasing the homogeneity of the precursor population. To validate our results 
it may be worthwhile to test again the transcriptional activation of BDNF VIII-IX transcript 
and the methylation states of the different iPS lines used in chapter 3 and 5 respectively with 
FACS-sorted NPC populations to prove that the obtained results were not due to contamina-
tion of the cell population. Others have proved it to be a valuable technique to enrich the NPC 
population63,64. It should be taken into consideration though that even populations selected by 
canonical marker expression may still present a diversity within their own subclass.
We used real-time quantitative PCR and EB differentiation to test pluripotency of our iPS 
lines. However, determining when to call a line a pluripotent stem cell line remains a topic for 
debate. Several tests and assays are available yet none of these tests provides exclusive proof for 
all the genetic, epigenetic, transcriptional and translational assets of a stem cell65. Momentarily 
the community is moving towards validation of stem cell lines by gene expression data by the 
algorithm provided by Pluritest66. By computationally comparing the gene expression data 
of induced stem cells to bona fide stem cells, a cut-off score determines when an induced 
line is considered a stem cell line. However, once validated, stem cell lines need revalidation 
after passaging, manipulation and colony picking, making it practically impossible to control 
the exact composition of an iPS population. Here also studies would benefit from improved 
iPS maintenance protocols, such as methods to minimize contamination of pluripotency by 
spontaneous differentiation.
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To define the different types of neural cells in the culture still remains challenging. However 
others are paving the way with single-cell analyses and systematic characterization on the 
basis of electrophysiological and transcriptomic profiles67. As the brain in development also 
depicts heterogeneity in vitro iPS-derived neural cultures may actually not stray too far from 
their in vivo counterparts68. Nonetheless, as pathways regarding cell fate decision and network 
formation in neuronal cultures are being explored and more knowledge on the different NPCs 
emerges, caution should be taken with treating every batch of NPCs and neuronal differentia-
tion similar. 
Reproducibility between labs is a concerning factor, as findings of previous researchers 
may prove non-repeatable and hence their results faulty. Comparable to iPS maintenance, 
protocols to generate reproducible neuronal cultures contain multiple steps, variables, and 
often, subjective judgment decisions. Clearer and more accurate experimental descriptions, 
improvement of induction protocols and pre-selection of NPC pools may benefit reproduc-
ibility between labs.
Overall, the extent to which acquired mutations in iPS lines, aberrant epigenomic mark-
ers, inherent genetic variability and heterogeneity in neural cultures hamper the ability to 
model human brain diseases seems to largely depend on the research question to be answered. 
Experimental conditions are to be tailored to these questions. Nonetheless, small effect sizes of 
genes, unidentified neural cell types, and the involvement of pathways in disease require the 
highest standard of iPS modeling. As such, the community at whole may do best to optimize 
iPS technology to its highest capacities to continue to unravel the molecular and cellular 
mechanisms underlying human brain disorders.
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SuMMary
For decades the study of living human brain-derived cell types was challenging. With the 
advent of stem cell technology this changed. Neural cells could now be generated from so-
matic cell types. With this technology a new opportunity for studying human brain diseases 
emerged.
In chapter 1 I give a brief overview of the complexity and development of the human cere-
bral cortex. I introduce stem cell technology and pose the question to what extent stem cell 
technology can be used to model human brain disorders.
In chapter 2 we describe a protocol to generate functional neuronal networks using hu-
man iPS. We show that these networks exist of different types of neuronal cells: neurons and 
astrocytes. In addition we show that the neurons are electrophysiologically active and suitable 
for modeling living human neurons.
In chapter 3 we use this protocol to generate different types of neural cells. We study the 
transcriptional regulation of BDNF transcript VIII-IX. BDNF is a neurotrophic factor that 
is of essence for brain development and proper structure of individual cells and networks. 
We find that BDNF transcript VIII-IX is highly upregulated in neural precursor cells that are 
chemically activated. This is not the case in mouse neural precursor cells. We also identified 
several new human BDNF transcripts using pluripotent stem cell-derived neuronal cells.
In chapter 4 we use our protocol to study subcellular localization of human UBE3A pro-
tein isoforms. Patients with the Angelman Syndrome have a dysfunctional maternal copy of 
the UBE3A gene. Comparisons between the mouse and human isoforms show that UBE3A 
isoforms are differentially located in neurons. Dissimilar localization suggests that the few 
differences between the mouse and human UBE3A gene sequence might be the critical deter-
minants of their distinct subcellular localization.
In chapter 5 we investigate the epigenetic effect of our reprogramming strategy on the FMR1 
gene. Absence of the product of this gene, the fragile X mental retardation protein (FMRP), 
causes the intellectual disability disorder fragile X. In the majority of the patients an expanded 
CGG repeat in the promoter region of this gene causes, by methylation, transcriptional silenc-
ing which leads to disease. This process takes place in early human embryonic development. 
We identified a healthy individual with a full mutation of the FMRI gene without concomi-
tant methylation. We find that in cell lines of this individual the FMRI promoter becomes 
methylated during reprogramming and stays methylated after differentiation into neuronal 
progenitors.
In chapter 6 we identify a genetic variant associated with Alzheimer’s disease (AD). This 
variant is annotated to the promoter region of the non-coding RNA miR-142. In iPS-derived 
neuronal progenitors we find that miR-142 regulates PICALM, a well-validated gene linked 
to AD.
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In chapter 7, I discuss the limitations of iPS technology that influence its capacity to model 
human brain diseases. I also discuss potential solutions.
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SaMenvaTTInG
Decennia lang was het bestuderen van levende humane hersencellen een uitdaging. Met de 
komst van de induceerbare stamcel technologie veranderde dit. Hersencellen konden vanaf 
nu gegenereerd worden van somatische cellen. Deze technologie creeërde daarom een nieuwe 
mogelijkheid om humane hersenaandoeningen te bestuderen.
In hoofdstuk 1 geef ik een kort overzicht van de complexiteit en de ontwikkeling van de 
humane cerebrale cortex. Ik introduceer stamcel technologie en stel de vraag in hoeverre 
stamcel technologie gebruikt kan worden om humane hersenaandoeningen te modeleren.
In hoofdstuk 2 beschrijven we een protocol om functionele neuronale netwerken te gener-
eren van humane geïnduceerde stamcellen. We laten zien dat deze netwerken uit verschillende 
neuronale cellen bestaan: neuronen en astrocyten. Deze neuronen zijn ook electrofysiologisch 
actief en presenteren zich als een goed model voor levende humane neuronen.
In hoofdstuk 3 gebruiken we dit protocol om verschillende neurale cellen te genereren. 
We bestuderen de transcriptionele regulatie van het BDNF transcript VIII-IX. BDNF is een 
neurotrofine dat van belang is voor hersenontwikkeling en opbouw van individuele cellen en 
netwerken. We vinden dat BDNF transcript VIII-IX sterk opgereguleerd wordt in neuronale 
voorloper cellen die chemisch geactiveerd zijn. Dit fenomeen vindt niet plaats in neuronale 
voorloper cellen in muizen. We identificeren ook enkele nieuwe humane BDNF transcripten 
door gebruik te maken van neuronale cellen die zijn afgeleid van stamcellen.
In hoofdstuk 4 gebruiken we ons protocol om de subcellulaire lokalisatie van het humane 
UBE3A eiwit te bestuderen. Patiënten met het Angelman Syndroom (AS) hebben een disfunc-
tioneel maternaal UBE3A gen. Vergelijkingen tussen de isovormen van de muis en de mens 
van het UBE3A eiwit laten zien dat er verschillen in lokalisatie zijn. Het verschil in lokalisatie 
suggeert dat de enkele verschillen tussen de DNA-sequentie van de mens en de muis wellicht 
verantwoordelijk kunnen zijn voor de verschillende sublokalisaties.
In hoofdstuk 5 bestuderen we het epigenetische effect van onze reprogrammeringsstrategie 
op het FMR1 gen. In afwezigheid van het product van dit gen, het fragile X mentale retardatie 
eiwit (FMRP), ontstaat de verstandelijke beperking fragile X Syndrome. Bij het merendeel 
van de patiënten zorgt een herhaling van het CGG patroon in de promoter regio van het gen 
door methylatie transcriptionele blokkade van FMR1 wat tot ziekte leidt. Dit proces vindt 
plaats in de vroege embryonale ontwikkeling. We identificeerden een gezond individu met 
een volledige mutatie van het FMR1 gen zonder bijgaande methylatie. We ondervonden dat 
door het reprogrammeren de promoter van het FMR1 gen werd gemethyleerd in cellijnen van 
dit individu en dat deze gemethyleerd bleef in neuronale voorloper cellen.
In hoofdstuk 6 identificeren we een genetische variant die verband houdt met de ziekte 
van Alzheimer. Deze variant bevindt zich in de promoter regio van het niet-coderende RNA 
miR-142. In neuronale voorloper cellen die zijn afgeleid van geïnduceerde stamcellen vinden 
168 Appendices
we dat miR-142 het gen PICALM reguleert. Dit gen werd al eerder in verband gebracht met 
de ziekte van Alzheimer.
In hoofdstuk 7 bespreek ik de limitaties van induceerbare stamcel technologie en hoe 
dit de capaciteit om hersenaandoeningen te modeleren beïnvloedt. Ook bespreek ik enkele 
potentiële oplossingen.
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